<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/ProjectMundo/style/jats-html.xsl"?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41467
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41467.2041-1723
   </journal-id>
   <journal-title-group>
    <journal-title>
     Nature Communications
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Nat Commun
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2041-1723
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41467-024-52388-1
   </article-id>
   <article-id pub-id-type="manuscript">
    52388
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41467-024-52388-1
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/308/575
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/4028/67/1990/283/1897
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/4028/67/1059/2325
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/250/1619/382
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /42/109
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /38/5
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /64/60
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /13/44
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /13/31
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /14
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     Uhariri wa CRISPR/Cas9 wa NKG2A unaboresha ufanisi wa seli za wauaji wa asili za CD33 zinazolengwa na chimeric antigen receptor
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" equal-contrib="yes" id="Au1">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0009-0009-2392-6416
     </contrib-id>
     <name name-style="western">
      <surname>
       Bexte
      </surname>
      <given-names>
       Tobias
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" equal-contrib="yes" id="Au2">
     <name name-style="western">
      <surname>
       Albinger
      </surname>
      <given-names>
       Nawid
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Al Ajami
      </surname>
      <given-names>
       Ahmad
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-5844-1587
     </contrib-id>
     <name name-style="western">
      <surname>
       Wendel
      </surname>
      <given-names>
       Philipp
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="aff" rid="Aff9">
      9
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <name name-style="western">
      <surname>
       Buchinger
      </surname>
      <given-names>
       Leon
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <name name-style="western">
      <surname>
       Gessner
      </surname>
      <given-names>
       Alec
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-4284-2006
     </contrib-id>
     <name name-style="western">
      <surname>
       Alzubi
      </surname>
      <given-names>
       Jamal
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff11">
      11
     </xref>
     <xref ref-type="aff" rid="Aff12">
      12
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au8">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-9565-2850
     </contrib-id>
     <name name-style="western">
      <surname>
       Särchen
      </surname>
      <given-names>
       Vinzenz
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff13">
      13
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au9">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-2650-586X
     </contrib-id>
     <name name-style="western">
      <surname>
       Vogler
      </surname>
      <given-names>
       Meike
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff13">
      13
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au10">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-1010-296X
     </contrib-id>
     <name name-style="western">
      <surname>
       Rasheed
      </surname>
      <given-names>
       Hadeer Mohamed
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff14">
      14
     </xref>
     <xref ref-type="aff" rid="Aff15">
      15
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au11">
     <name name-style="western">
      <surname>
       Jung
      </surname>
      <given-names>
       Beate Anahita
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff14">
      14
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au12">
     <name name-style="western">
      <surname>
       Wolf
      </surname>
      <given-names>
       Sebastian
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au13">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-0865-9582
     </contrib-id>
     <name name-style="western">
      <surname>
       Bhayadia
      </surname>
      <given-names>
       Raj
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au14">
     <name name-style="western">
      <surname>
       Oellerich
      </surname>
      <given-names>
       Thomas
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au15">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-1070-0727
     </contrib-id>
     <name name-style="western">
      <surname>
       Klusmann
      </surname>
      <given-names>
       Jan-Henning
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au16">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-4876-802X
     </contrib-id>
     <name name-style="western">
      <surname>
       Penack
      </surname>
      <given-names>
       Olaf
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff14">
      14
     </xref>
     <xref ref-type="aff" rid="Aff16">
      16
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au17">
     <name name-style="western">
      <surname>
       Möker
      </surname>
      <given-names>
       Nina
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff17">
      17
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au18">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-7757-4630
     </contrib-id>
     <name name-style="western">
      <surname>
       Cathomen
      </surname>
      <given-names>
       Toni
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff11">
      11
     </xref>
     <xref ref-type="aff" rid="Aff12">
      12
     </xref>
     <xref ref-type="aff" rid="Aff18">
      18
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au19">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-4158-5872
     </contrib-id>
     <name name-style="western">
      <surname>
       Rieger
      </surname>
      <given-names>
       Michael A.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
     <xref ref-type="aff" rid="Aff19">
      19
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au20">
     <name name-style="western">
      <surname>
       Imkeller
      </surname>
      <given-names>
       Katharina
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" corresp="yes" id="Au21">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-8530-1192
     </contrib-id>
     <name name-style="western">
      <surname>
       Ullrich
      </surname>
      <given-names>
       Evelyn
      </given-names>
     </name>
     <address>
      <email>
       evelyn@ullrichlab.de
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="corresp" rid="IDs41467024523881_cor21">
      x
     </xref>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt, Department of Pediatrics
      </institution>
      <institution content-type="org-name">
       Experimental Immunology and Cell Therapy
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt
      </institution>
      <institution content-type="org-name">
       Department of Pediatrics
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff3">
     <label>
      3
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.511198.5
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt
      </institution>
      <institution content-type="org-name">
       Frankfurt Cancer Institute
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff4">
     <label>
      4
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/02y3dtg29
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.433743.4
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 1093 4868
      </institution-id>
      <institution content-type="org-division">
       German Red Cross Blood Service Baden-Württemberg – Hessen
      </institution>
      <institution content-type="org-name">
       Institute for Transfusion Medicine and Immunohematology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff5">
     <label>
      5
     </label>
     <institution-wrap>
      <institution content-type="org-name">
       University Cancer Center (UCT)
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff6">
     <label>
      6
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt, University Hospital
      </institution>
      <institution content-type="org-name">
       Neurological Institute / Edinger Institute
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff7">
     <label>
      7
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/05n911h24
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.6546.1
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 0940 1669
      </institution-id>
      <institution content-type="org-division">
       Institute for Organic Chemistry and Biochemistry
      </institution>
      <institution content-type="org-name">
       Technical University of Darmstadt
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Darmstadt
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff8">
     <label>
      8
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Consortium (DKTK) partner site Frankfurt/Mainz
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff9">
     <label>
      9
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cdgtt98
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Research Center (DKFZ)
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Heidelberg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff10">
     <label>
      10
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt, University Hospital
      </institution>
      <institution content-type="org-name">
       Department of Medicine II - Hematology and Oncology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff11">
     <label>
      11
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/0245cg223
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.5963.9
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0491 7203
      </institution-id>
      <institution content-type="org-division">
       Institute for Transfusion Medicine and Gene Therapy
      </institution>
      <institution content-type="org-name">
       Medical Center – University of Freiburg
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Freiburg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff12">
     <label>
      12
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/0245cg223
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.5963.9
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0491 7203
      </institution-id>
      <institution content-type="org-division">
       Center for Chronic Immunodeficiency
      </institution>
      <institution content-type="org-name">
       Faculty of Medicine, University of Freiburg
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Freiburg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff13">
     <label>
      13
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt
      </institution>
      <institution content-type="org-name">
       Institute for Experimental Pediatric Hematology and Oncology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff14">
     <label>
      14
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/001w7jn25
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.6363.0
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2218 4662
      </institution-id>
      <institution content-type="org-division">
       Charité, University Berlin and Humboldt-University Berlin, Department of Hematology
      </institution>
      <institution content-type="org-name">
       Oncology and Tumor Immunology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Berlin
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff15">
     <label>
      15
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00mzz1w90
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7155.6
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2260 6941
      </institution-id>
      <institution content-type="org-division">
       Clinical Pathology Department, Faculty of Medicine
      </institution>
      <institution content-type="org-name">
       Alexandria University
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Alexandria
     </addr-line>
     <country country="EG">
      Egypt
     </country>
    </aff>
    <aff id="Aff16">
     <label>
      16
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Consortium (DKTK) partner site Berlin
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Berlin
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff17">
     <label>
      17
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.59409.31
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0552 5033
      </institution-id>
      <institution content-type="org-name">
       Miltenyi Biotec B.V. &amp; Co. KG
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Bergisch Gladbach
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff18">
     <label>
      18
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Consortium (DKTK) partner site Freiburg
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Freiburg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff19">
     <label>
      19
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04ckbty56
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.511808.5
      </institution-id>
      <institution content-type="org-name">
       Cardio-Pulmonary-Institute
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <fn fn-type="equal" id="fn1">
     <p>
      These authors contributed equally: Tobias Bexte, Nawid Albinger.
     </p>
    </fn>
    <corresp id="IDs41467024523881_cor21">
     <label>
      x
     </label>
     <email>
      evelyn@ullrichlab.de
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     30
    </day>
    <month>
     9
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    15
   </volume>
   <issue seq="8439">
    1
   </issue>
   <elocation-id>
    8439
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      5
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="received">
     <day>
      17
     </day>
     <month>
      1
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="accepted">
     <day>
      30
     </day>
     <month>
      8
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="online">
     <day>
      30
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © The Author(s) 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     The Author(s)
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
       http://creativecommons.org/licenses/by/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     Maelezo ya Mfupi
    </title>
    <p id="Par1">
     Seli za wauaji wa asili (NK) zilizobadilishwa na chimeric antigen receptor (CAR) zinaonyesha shughuli dhidi ya saratani ya myeloid ya kuambukiza (AML) katika maumbile. Hata hivyo, uauaji wa tumor kwa seli za NK mara nyingi huathiriwa na mwingiliano kati ya antigen ya leukocyte ya binadamu (HLA)-E na reseptori ya kizuizi, NKG2A. Hapa, tunaelezea mkakati ambao unashinda uzuiaji wa seli za NK-CAR uliosababishwa na kizuizi cha kinga cha HLA-E-NKG2A. Tunazalisha seli za NK za CD33 zinazolengwa na AML (CAR33) zilizoambatishwa na uharibifu wa jeni ya NKG2A-encoding
     <italic>
      KLRC1
     </italic>
     kwa kutumia CRISPR/Cas9. Kwa kutumia uchanganuzi wa seli moja ya multi-omics, tuligundua sifa za uandikaji wa seli za CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK za kuimarika na kukomaa, ambazo zimehifadhiwa baada ya kugongana na seli za AML. Zaidi ya hayo, seli za CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK zinaonyesha shughuli kali ya uauaji wa AML dhidi ya mstari wa seli za AML na blasts za msingi katika vitro na maumbile. Kwa hivyo, tunahitimisha kuwa seli za NK zisizo na NKG2A zina uwezo wa kuepuka kizuizi cha kinga katika AML.
    </p>
   </abstract>
   <abstract abstract-type="ShortSummary" id="Abs2" xml:lang="en">
    <p id="Par2">
     NK cell-based therapy can kill acute myeloid leukemia (AML), but immune suppression may occur. Here the authors overcome the immunosuppression of AML-targeted CAR33-NK cells via non-viral CRISPR-editing of the immune checkpoint NKG2A, leading to an enhanced potency of the CAR-NK cell product with sustained anti-tumor efficacy.
    </p>
   </abstract>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1107">
      Immunology
     </kwd>
    </nested-kwd>
   </kwd-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      8439
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      9
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      5
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41467_2024_Article_52388.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1" sec-type="introduction">
   <title>
    Utangulizi
   </title>
   <p id="Par3">
    Utafiti kuhusu matibabu mapya ya chimeric antigen receptor (CAR)-T cell umesababisha idhini ya bidhaa nyingi kwa matibabu ya ugonjwa wa seli ya B
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     ,
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
     ,
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
     ,
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
     ,
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
    </sup>
    . Zaidi ya matibabu ya CAR-T cell yaliyoidhiniwa na U.S. Food and Drug Administration na European Medicines Agency, CD19-targeting CAR-natural killer (NK) cells zilionekana kuwa salama na kuwa na ufanisi sawa na CAR-T cells katika jaribio la kimatibabu
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    . Maendeleo ya bidhaa za CAR kwa matibabu ya ugonjwa wa leukemia ya myeloid (AML) ni changamoto zaidi kwa sababu ya ugonjwa huo kuwa na aina nyingi na ukosefu wa aina za antigens za AML pekee
    <sup>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
     ,
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    . Hata hivyo, mojawapo ya antigen inayowezekana kwa matibabu ya seli ya CAR ni CD33, ambayo inaonyeshwa kwenye seli za leukemic na seli zinazosababisha leukemia katika hadi 88% ya wagonjwa wa AML, na matokeo ya kabla ya kimatibabu yameonyesha shughuli ya anti-AML ya CD33-specific CAR-T cells
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
     ,
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     ,
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
    </sup>
    . Mojawapo ya chaguzi zinazowezekana kwa matibabu ya CAR-T cell ni seli za NK zinazotumwa, ambazo zina muda mfupi wa maisha kuliko seli za T, zinahusishwa na athari chache za upande, na zina uwezo wa asili wa kuua seli bila kutegemea CAR, ambao umethibitishwa katika muktadha wa NKG2D-ligand-expressing AML
    <sup>
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
     ,
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
     ,
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
     ,
     <xref ref-type="bibr" rid="CR17">
      17
     </xref>
     ,
     <xref ref-type="bibr" rid="CR18">
      18
     </xref>
    </sup>
    .
   </p>
   <p id="Par4">
    Katika kazi yetu ya hivi karibuni, tulitengeneza seli za NK za awali zinazolenga CD33 (CAR33)-NK ambazo zilionyesha kuongezeka kwa shughuli ya antileukemic dhidi ya seli za AML za CD33 katika muundo wa xenograft in vivo
    <sup>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
    </sup>
    . Hata hivyo, ufanisi wa seli za CAR33-NK unaweza kuwa na vikwazo kwa sababu ya kuongezeka kwa viwango vya viwango vya kinga ya kinga katika mazingira ya tumor yenye sumu ya kinga. Kwa kweli, utoaji wa seli za NK unadhibitiwa kwa karibu na usawa wa ishara za kuchochea na kuzuia zinazotolewa na aina mbalimbali za wavutio vilivyowekwa kwenye uso wa seli. Miongoni mwao, mojawapo ya wavutio muhimu wa kuzuia ni NK group 2A (NKG2A) ambayo imeandikwa na jeni ya
    <italic>
     KLRC1
    </italic>
    . Inaunganisha na protini ya MHC I isiyo ya kawaida ya HLA-E, ambayo mara nyingi huongezwa kwenye seli za seli za seli
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
     ,
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     ,
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Tumethibitisha pamoja na wengine kwamba kuvunja mhimili wa NKG2A-HLA-E kwa kutumia antibodies za kuzuia NKG2A, kama vile monalizumab au CRISPR/Cas9-based ya
    <italic>
     KLRC1
    </italic>
    katika seli za NK, inaweza kuongeza kwa kiasi kikubwa uwezo wa kuua seli za NK dhidi ya myeloma ya mara kwa mara
    <sup>
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Tumegundua zaidi kwamba aina mbalimbali za seli za AML, na pia seli za AML za awali, zinaonyesha viwango vya juu vya HLA-E, na kwamba usemi wa HLA-E unapoongezeka baada ya kukutana na IFN-γ, cytokine inayojulikana kuwa na viwango vya juu vilivyotolewa na seli za CAR-NK baada ya kukutana na seli za lengo. Kwa hivyo, tulidhania kuwa mhimili wa NKG2A-HLA-E unaweza kuwa na jukumu muhimu katika kuchoka kwa seli za CAR-NK na kwamba kuondoa jeni ya
    <italic>
     KLRC1
    </italic>
    katika seli za NK za CD33 zinazolengwa na CAR ingeboa uwezo wao wa kuua AML
    <sup>
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    .
   </p>
   <p id="Par5">
    Katika kazi hii, tunaelezea utengenezaji wa seli za NK za kawaida zilizo na mabadiliko mawili kwa kuchanganya usakinishaji wa lentiviral wa CAR33 na uharibifu wa jeni ya
    <italic>
     KLRC1
    </italic>
    kwa njia ya CRISPR/Cas9. Seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zilizotokana zilionyesha uwezo wa kuua seli ulioongezeka kwa kiasi kikubwa ikilinganishwa na seli za CAR33-NK au
    <italic>
     KLRC1
    </italic>
    -NK dhidi ya seli za CD33/HLA-E za OCI-AML2 na kundi la seli za awali za msingi za wagonjwa
    <sup/>
    .
   </p>
   <p id="Par6">
    Kupima kwa kina kwa seli moja na vipimo vya epitope vilionyesha muundo wa usemi wa jeni unaohusisha utendakazi, ukomavu na uwezo wa kuua seli katika seli za CAR33-NK na seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zilizo na mabadiliko mawili, kwa kufanana na uwezo wa kuua seli ulioongezeka. Kwa kuongeza, seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zilionyesha ongezeko la IFN-γ ikilinganishwa na seli za
    <italic>
     KLRC1
    </italic>
    -NK na CAR33-NK zilizo na mabadiliko moja, ambayo ilidumishwa baada ya kukutana na seli za lengo
    <sup/>
    .
   </p>
   <p id="Par7">
    Matokeo yetu yanasisitiza uwezo wa kimatibabu wa kubadilisha muundo wa wavutio wa seli za NK kwa kuchanganya uhandisi wa CAR-NK na uhariri wa jeni ili kuondoa wavutio wa kuzuia
    <sup>
     <xref ref-type="bibr" rid="CR26">
      26
     </xref>
    </sup>
    . Mabadiliko ya hali ya juu yanafungua safu ya uwezekano na yanapaswa kuzingatiwa wakati wa kubuni matibabu ya seli za kinga ili kulenga magonjwa yenye mahitaji yasiyotimiza.
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    Matokeo
   </title>
   <sec id="Sec3">
    <title>
     SEL-NK za Kijeni mbili zilizoundwa CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     zinachanganya uingizwaji wa CAR na usemi uliopunguzwa wa NKG2A
    </title>
    <p id="Par8">
     Selio la CAR33-NK lilizalishwa kwa kutumia mchakato wa transduction ya lentivirus kwa seli za awali za NK zilizotolewa kutoka kwa damu ya periferal (PB) ya wadonaji walio na afya (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1a
     </xref>
     ) ili kueleza CAR ya kizazi cha pili inayolenga CD33 kama inavyoonyeshwa katika Fig.
     <xref ref-type="fig" rid="Fig1">
      1a
     </xref>
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
     </sup>
     . Baada ya mchakato wa transduction, usemi wa CAR ulifikiwa katika 30-70% ya seli za NK (Fig.
     <xref ref-type="fig" rid="Fig1">
      1b, c
     </xref>
     ). Kwa ajili ya knockout ya NKG2A, seli za NK zisizotumika (NT)-NK na CAR33-NK zilichanganywa na ribonucleoprotein (RNP) changamano ya CRISPR/Cas9 inayolenga eneo la
     <italic>
      KLRC1
     </italic>
     . Uhamishaji wa RNP usio na virusi ulisababisha kupungua kwa kiasi kikubwa kwa seli zinazoonyesha NKG2A kwa ~50% ikilinganishwa na seli za NK zisizotumika (NT)-NK (~90% NKG2A) (Fig.
     <xref ref-type="fig" rid="Fig1">
      1b, d
     </xref>
     ). Ufanisi wa mara kwa mara wa
     <italic>
      KLRC1
     </italic>
     ulithibitishwa kwa seli za NK zilizohaririwa katika uwepo au kutokuwepo kwa CAR, kwa kutumia T7 endonuclease 1 (T7E1; &gt;67%) na kuhesabu ubadilishaji wa uingizwaji/ufutaji (indels) kwa uchanganuzi wa Inference of CRISPR Edits (ICE; &gt;90%) (Fig.
     <xref ref-type="fig" rid="Fig1">
      1e, f
     </xref>
     ; Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1b
     </xref>
     <sup/>
     . Uchambuzi wa usambazaji wa indel ulionyesha kuongezeka kwa +1 kuingizwa kufuatwa na −15 kufutwa kati ya wadonaji tofauti watatu katika uwepo au kutokuwepo kwa CAR. Kufuta kwa −15 kunaweza kuelezewa na kuwepo kwa mfuatano wa micro-homology unaozunguka sehemu ya kukatwa (Fig.
     <xref ref-type="fig" rid="Fig1">
      1f
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1c
     </xref>
     ,
     <xref ref-type="supplementary-material" rid="MOESM1">
      1d
     </xref>
     ). Kuongezeka kwa ukuaji uliongezeka kwa usawa katika hali zote nne kwa wakati (NT-NK cells,
     <italic>
      KLRC1
     </italic>
     -NK cells, CAR33-NK cells na CAR33-CAR-
     <italic>
      KLRC1
     </italic>
     -NK cells; onyesha katika kiwango cha kuongezeka kwa log, Fig.
     <xref ref-type="fig" rid="Fig1">
      1g
     </xref>
     ). Hata hivyo, tuliona kupungua kwa muda kwa idadi ya seli baada ya uchakataji wa msukosuko wa umeme wa nucleofection ili kuzalisha knockout ya jeni ya RNP (Fig.
     <xref ref-type="fig" rid="Fig1">
      1g
     </xref>
     ). Kupungua kwa idadi ya seli ilihusiana moja kwa moja na mchakato wa nucleofection siku ya 9 (tarehe ya kuzalisha knockout ya
     <italic>
      KLRC1
     </italic>
     ), lakini majibu yote ya seli yalipona na kuonyesha viwango vya ukuaji sawa kutoka siku ya 13 (Fig.
     <xref ref-type="fig" rid="Fig1">
      1g
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S2a–c
     </xref>
     ). Nucleofection na sgRNAs zisizohusiana au MOCK nucleofection ilisababisha kiwango sawa cha ukuaji wa seli za NK ikilinganishwa na sgRNA inayolenga
     <italic>
      KLRC1
     </italic>
     katika seli za CAR33-NK na NT-NK (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S2b, c
     </xref>
     ). Muhimu, uhariri wa CRISPR/Cas9 wa
     <italic>
      KLRC1
     </italic>
     katika seli za CAR33-NK ulionyesha uhariri wa jeni unaofaa ambao ulisababisha kupungua kwa kiasi kikubwa kwa usemi wa NKG2A kwenye uso wa seli (Fig.
     <xref ref-type="fig" rid="Fig1">
      1b
     </xref>
     )
     <sup/>
     .
     <fig id="Fig1" position="float">
      <label>
       Fig. 1
      </label>
      <caption xml:lang="sw">
       <title>
        Mchakato wa kuzalisha na kutathmini CRISPR/Cas9 knockout kwa CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK cells.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mfumo wa kuzalisha in vitro ya msingi CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK cells.
        <bold>
         b
        </bold>
        Mfano wa ploti za flow cytometry za usemi wa CAR33 na NKG2A kwenye seli zilizoathiriwa za NK.
        <bold>
         c
        </bold>
        Tathmini ya usemi wa uso wa CAR33 kwa kutumia flow cytometry kwa wakati (
        <italic>
         n
        </italic>
        = 6–9). Mean ± SD. CAR33 vs CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        : d14 (
        <italic>
         n
        </italic>
        = 0.1158), d21 (
        <italic>
         n
        </italic>
        = 0.1296), d28 (
        <italic>
         n
        </italic>
        = 0.8095).
        <bold>
         d
        </bold>
        Tathmini ya usemi wa NKG2A kwa kutumia flow cytometry baada ya knockout ya
        <italic>
         KLRC1
        </italic>
        kwa CRISPR/Cas9 (
        <italic>
         n
        </italic>
        = 7). Mean ± SD.
        <bold>
         e
        </bold>
        Uwiano wa ubadilishaji wa
        <italic>
         KLRC1
        </italic>
        kwenye kiwango cha jeni ulitathminiwa kwa kutumia Inference of CRISPR Edits (ICE) na T7E1 assay kwa seli za NK zilizobadilishwa na CAR (+CAR) na seli za NK za udhibiti (−CAR) (
        <italic>
         n
        </italic>
        = 3). Mean ± SD.
        <bold>
         f
        </bold>
        Mifano ya usambazaji wa indel (insertion/deletion) ilionyesha kwa uchanganuzi wa ICE kutoka kwa wadonaji tofauti (D1, D2, D3).
        <bold>
         g
        </bold>
        Uwiano wa upanuzi na mchakato wa uzalishaji wa seli za NK zisizoathiriwa (NT)-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK katika uwepo wa IL-2 (500 U/mL) na IL-15 (10 ng/ml Miltenyi Biotec au 50 ng/mL CellGenix) (
        <italic>
         n
        </italic>
        = 7). Mean ± SD (ns = 0.9991). Tathmini ya takwimu ilifanywa kwa kutumia two-way ANOVA (
        <bold>
         c
        </bold>
        ,
        <bold>
         g
        </bold>
        ) na jaribio la t la mwanafunzi (
        <bold>
         d
        </bold>
        ,
        <bold>
         e
        </bold>
        ). Kipengele cha
        <italic>
         n
        </italic>
        ni nakala za kibaolojia (kutoka kwa wadonaji wa afya tofauti) (
        <bold>
         c
        </bold>
        –
        <bold>
         e
        </bold>
        ,
        <bold>
         g
        </bold>
        ).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig1_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec4">
    <title>
     Uchambuzi wa Multi-omics unaonyesha hali ya seli iliyowashwa ya CAR33-(
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     )-NK
    </title>
    <p id="Par9">
     Ili kuchunguza athari iliyosababishwa na usemi wa CAR33 na/au knockout ya
     <italic>
      KLRC1
     </italic>
     katika seli za NK, tulihesabu usemi wa jeni na alama za uso kwa kiwango cha seli moja kwa kutumia mbinu ya amplicon-based cellular indexing of transcriptomes na epitopes kwa mchakato wa kuhesabu (CITE-seq). Kwa hiyo, seli za NK nne (NT,
     <italic>
      KLRC1
     </italic>
     , CAR33 na CAR33-
     <italic>
      KLRC1
     </italic>
     ) kutoka kwa wadonaji wawili tofauti zilichaguliwa kwa kutumia uchambuzi wa mtiririko wa damu (Fig.
     <xref ref-type="fig" rid="Fig2">
      2a
     </xref>
     ) ili kupata idadi ya seli za NK zinazoonyesha CAR (kwa CAR33 na CAR33-
     <italic>
      KLRC1
     </italic>
     ) na/au NKG2A hasi (kwa
     <italic>
      KLRC1
     </italic>
     na CAR33-
     <italic>
      KLRC1
     </italic>
     ) karibu 100%. Baada ya udhibiti wa ubora na kuchuja kwa data ya CITE-seq, jumla ya seli 32,908 na 20,197 kutoka kwa wadonaji D1 na D2, mtawalia, zilichambuliwa katika mchakato wa hesabu uliojumuishwa. Tuliunda mfano wa takwimu uliotumia data ya seli moja ili kugundua mabadiliko ya jumla ya usemi unaosababishwa na ubadilishaji wa jeni moja au mbili. Mfano wetu wa takwimu ulijumuisha vigeu vinne na ulihesabu kwa wakati mmoja utofauti wa kati ya wadonaji, athari ya CAR (Fig.
     <xref ref-type="fig" rid="Fig2">
      2b
     </xref>
     ), athari ya
     <italic>
      KLRC1
     </italic>
     (Fig.
     <xref ref-type="fig" rid="Fig2">
      2c
     </xref>
     ) pamoja na athari ya kujumlisha ya ubadilishaji wa jeni mbili (CAR:
     <italic>
      KLRC1
     </italic>
     , Fig.
     <xref ref-type="fig" rid="Fig2">
      2d
     </xref>
     ). Kumbuka, mabadiliko ambayo mfano hutambua kama ushirikiano wa CAR:
     <italic>
      KLRC1
     </italic>
     ni mabadiliko yanayoonekana katika seli za NK za CAR33-
     <italic>
      KLRC1
     </italic>
     ambazo hayawezi kuelezewa na mchanganyiko rahisi wa CAR na
     <italic>
      KLRC1
     </italic>
     (Fig.
     <xref ref-type="fig" rid="Fig2">
      2d
     </xref>
     ). Mabadiliko makubwa zaidi ya usemi wa jeni na protini zilionekana baada ya kuanzishwa kwa CAR inayolenga CD33 katika seli za NK (Fig.
     <xref ref-type="fig" rid="Fig2">
      2b
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3a
     </xref>
     ). Seli za CAR33 zilizoonyeshwa zilikuwa na viwango vya juu vya jeni zinazofasiri protini za MHC darasa II, kama vile
     <italic>
      HLA-DQA1, HLA-DQB1
     </italic>
     ,
     <italic>
      HLA-DRA, HLA-DPB1
     </italic>
     , na HLA darasa II histocompatibility antigen gamma chain (
     <italic>
      CD74
     </italic>
     ) ikilinganishwa na seli za NK zisizotumika (NT)-NK (Fig.
     <xref ref-type="fig" rid="Fig2">
      2b
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3a
     </xref>
     ). Usemi wa jeni hizi mara nyingi huonekana katika seli za T zilizoonyeshwa, na kuongezeka kwao katika majaribio yetu kunaweza kuwa na uhusiano na kuchochea njia za ishara za chini za TCR au CAR. Seli za CAR33 zilizoonyeshwa pia zilikuwa na viwango vya juu vya usemi wa jeni za alama za utayari na kuhamasishwa kama vile FcγRIIIa/CD16, CD70, integrin alpha M (CD11b), na interleukin-2 receptor alpha chain (IL2Rα/CD25), pamoja na alama za uhamaji kama vile C-C chemokine receptor type 2 (
     <italic>
      CCR2
     </italic>
     ) na C-X-C chemokine receptor type 4 (
     <italic>
      CXCR4
     </italic>
     ) (Fig.
     <xref ref-type="fig" rid="Fig2">
      2b
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3a
     </xref>
     ). Jeni zinazofasiri protini zinazoonyeshwa kwenye seli zisizokomaa au zilizozuia ziliongezwa chini baada ya kuanzishwa kwa CAR33 ikilinganishwa na seli za NK zisizotumika (NT)-NK (Fig.
     <xref ref-type="fig" rid="Fig2">
      2b
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3a
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
     </sup>
     . Kwa kuzingatia, knockout ya
     <italic>
      KLRC1
     </italic>
     katika seli za NK ilisababisha mabadiliko madogo katika muundo wa usemi wa jeni na protini na kuongezeka kwa wastani wa FcγRIIIa/CD16 na kupungua kwa
     <italic>
      ZNF683
     </italic>
     ikilinganishwa na seli za NK zisizotumika (NT)-NK (Fig.
     <xref ref-type="fig" rid="Fig2">
      2c
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3a
     </xref>
     ). Hatimaye, mchanganyiko wa usemi wa CAR33 na knockout ya
     <italic>
      KLRC1
     </italic>
     haikupelekea mabadiliko ya ziada katika usemi wa jeni na alama za uso ikilinganishwa na seli za NK zilizoonyeshwa kwa njia moja (CAR33 au
     <italic>
      KLRC1
     </italic>
     ) (Fig.
     <xref ref-type="fig" rid="Fig2">
      2d
     </xref>
     ). Mbinu yetu ya hesabu iligundua ushirikiano kati ya usemi wa CAR33 na
     <italic>
      KLRC1
     </italic>
     , na kusababisha kuongezeka kwa
     <italic>
      ZNF683
     </italic>
     na chemokine (C-C motif) ligand 1 (
     <italic>
      CCL1
     </italic>
     ), na kupungua kwa
     <italic>
      CCR2
     </italic>
     (Fig.
     <xref ref-type="fig" rid="Fig2">
      2d
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3a
     </xref>
     ). Hii, hata hivyo, inaweza kuelezewa na ukweli kwamba mabadiliko yanayosababishwa na CAR33 na
     <italic>
      KLRC1
     </italic>
     hayajumuishwi katika ubadilishaji wa jeni mbili: Kwa mfano, ubadilishaji wa jeni wote wawili huchangia kupungua kwa
     <italic>
      ZNF683
     </italic>
     , wakati mchanganyiko wa ubadilishaji wa jeni mbili haupunguzi zaidi usemi wa
     <italic>
      ZNF683
     </italic>
     . Kwenye kiwango cha protini, uchanganuzi wa usemi wa protini kwa Ab-seq na uchanganuzi wa mtiririko wa damu wa mchanganyiko mbalimbali wa seli za NK za uhandisi jeni ulionyesha hakuna mabadiliko ya alama za seli za NK za kawaida (Fig.
     <xref ref-type="fig" rid="Fig2">
      2e, f
     </xref>
     ). Kuongezeka kwa wastani kwa CD16 kilithibitishwa katika Ab-seq na uchanganuzi wa mtiririko wa damu, pamoja na fenotaipe ya mara kwa mara ya wavutio muhimu wa seli za NK kama vile CD56, DNAM1 (CD314), NKG2D (CD226), CD57, NKp44, NKp30 (Fig.
     <xref ref-type="fig" rid="Fig2">
      2e, f
     </xref>
     ). Pia, hakuna tofauti zilizoonekana kwa usemi wa CD69, TIGIT au TIM-3 kati ya mchanganyiko wa seli za NK nne (Fig.
     <xref ref-type="fig" rid="Fig2">
      2e, f
     </xref>
     )
     <sup/>
     .
     <fig id="Fig2" position="float">
      <label>
       Fig. 2
      </label>
      <caption xml:lang="sw">
       <title>
        Usemi wa CAR33 na knockout ya
        <italic>
         KLRC1
        </italic>
        husababisha mabadiliko katika nakala za jeni na lakini si katika nakala za alama za uso za seli za NK.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mfumo wa mpangilio wa uchambuzi wa seli za NK za kibinafsi wa sehemu nne za seli za NK. Seli za NK za CAR zilichaguliwa kwa kutumia CAR+,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK zilichaguliwa kwa kutumia NKG2A- na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK zilichaguliwa kwa kutumia CD33+/NKG2A− NK kabla ya uchanganuzi wa CITE-Seq.
        <bold>
         b
        </bold>
        -
        <bold>
         d
        </bold>
        Mabadiliko ya jumla ya nakala za jeni (RNA) katika seli za NK baada ya kuanzishwa kwa CAR33 (
        <bold>
         b
        </bold>
        ), knockout ya
        <italic>
         KLRC1
        </italic>
        (
        <bold>
         c
        </bold>
        ) na athari za kushirikiana za CAR33 na knockout ya
        <italic>
         KLRC1
        </italic>
        (
        <bold>
         d
        </bold>
        ). Jaribio la takwimu: quasi-likelihood (QL) F-test dhidi ya kiwango (
        <bold>
         b
        </bold>
        –
        <bold>
         d
        </bold>
        ). Mifano ya volcano inaonyesha uchanganuzi uliojumuishwa wa seli za NK kutoka kwa wadonaji D1 na D2 na inaonyesha thamani ya
        <italic>
         p
        </italic>
        -iliyobadilishwa (
        <italic>
         y
        </italic>
        -axis) na logFC iliyoonyeshwa (
        <italic>
         x
        </italic>
        -axis) kwa kila kipengele cha jeni na kwa kila ubadilishaji wa jeni (CAR33 (
        <bold>
         b
        </bold>
        ),
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        (
        <bold>
         c
        </bold>
        ), athari za kushirikiana za CAR33 na
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        (
        <bold>
         d
        </bold>
        )). Sifa zilizoongezwa na zilizopunguzwa zimeonyeshwa kwa rangi. Mstari wa wima unaonyesha FDR ya 5% na mistari ya wima inaonyesha anuwai ya logFC kati ya −log2 (1.2) na log2 (1.2). Jeni zilizochaguliwa zimeonyeshwa kwa lebo. Jaribio la takwimu: quasi-likelihood (QL) F-test dhidi ya kiwango.
        <bold>
         e
        </bold>
        Usambazaji wa alama za uso kutoka kwa data ya CITE-Seq kwa ajili ya sehemu nne za seli za NK. Usambazaji unaonyeshwa kama msongamano, na eneo lililofunika limepunguzwa hadi 1.
        <bold>
         f
        </bold>
        Usemi wa alama za uso za vipandikizi tofauti vya seli za NK vilivyopimwa kwa kutumia flow cytometry. Mfano wa histogram unaonyeshwa.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig2_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par10">
     Kisha tuliichambua pamoja RNA na protini usemi profails kwa kiwango cha seli moja ili kuchunguza kama mabadiliko ya jumla ya usemi yaliyoonekana yalihusiana na vikundi maalum vya seli (Fig.
     <xref ref-type="fig" rid="Fig3">
      3
     </xref>
     ). Zote mbili, RNA na protini usemi kwa kiwango cha seli moja kuthibitisha fenotaipe ya seli za NK na ukosefu wa alama za seli za T (tazama Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3b, c
     </xref>
     ). Kwa kuzingatia, muundo wa
     <italic>
      KLRC1
     </italic>
     -NK seli iliyofanana na ile ya NT-NK na muundo wa CAR33-NK ilikuwa zaidi inafanana na ile ya CAR33-
     <italic>
      KLRC1
     </italic>
     -NK seli (Fig.
     <xref ref-type="fig" rid="Fig3">
      3a–c
     </xref>
     ). Mchanganyiko wa kujumuishwa wa seli za NK usemi profails kutoka kwa mchanganyiko wote wa seli nne uligundua vikundi sita vya seli na hali tofauti za kimatibabu (Fig.
     <xref ref-type="fig" rid="Fig3">
      3c–e
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3d
     </xref>
     ). Ili kuelezea kwa utendakazi tofauti za kimatibabu, tuligawa vipengele vya jeni au protini vilivyochaguliwa kulingana na kazi zao katika “
     <italic>
      Checkpoint &amp; Suppressive Regulators
     </italic>
     ”, “
     <italic>
      Downstream TCR signaling
     </italic>
     ”, “
     <italic>
      Lymphocyte Activation
     </italic>
     ”, au “
     <italic>
      Mature NK Cells
     </italic>
     ” (Fig.
     <xref ref-type="fig" rid="Fig3">
      3f, g
     </xref>
     ). Mchanganyiko wa seli za NT-NK ulijumuisha kwa kiasi kikubwa seli kutoka kwa kundi la kimatibabu 3, ambalo lilikuwa na sifa za usemi wa jeni zinazohusiana na kiwango cha chini cha kuhamasishwa kwa seli za NK na utayari (Fig.
     <xref ref-type="fig" rid="Fig2">
      2e–g
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3d
     </xref>
     ). Seli za
     <italic>
      KLRC1
     </italic>
     -NK zilionyesha sehemu kubwa ya seli zinazohusiana na kundi la kimatibabu 4, ambalo lilijumuisha jeni za seli za NK zinazohusiana na utayari (Fig.
     <xref ref-type="fig" rid="Fig2">
      2e–g
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3d
     </xref>
     ). Kinyume chake, muundo wa seli za CAR33-NK ulikuwa kwa kiasi kikubwa unaohusiana na vikundi vya kimatibabu 1, 2, na 6, ambapo seli zilikuwa na sifa za seli za NK zilizoonyeshwa na zilizotayarishwa na njia za ishara za chini za TCR, lakini pia njia za kudhibiti za kinga za kinga (Fig.
     <xref ref-type="fig" rid="Fig3">
      3e–g
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3d
     </xref>
     ). Kuhusu seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK, muundo wa kimatibabu unaweza kugawanywa kama vile seli za CAR33-NK zinazohusiana na kuhamasishwa na ishara za chini za TCR (vikundi 1, 2 na 6)
     <sup/>
     .
     <fig id="Fig3" position="float">
      <label>
       Fig. 3
      </label>
      <caption xml:lang="sw">
       <title>
        Chembe za CAR33- na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK zina sehemu kubwa ya seli zenye sifa za kemikali za NK zilizoimarishwa, zimekomaa.
       </title>
       <p>
        <bold>
         a
        </bold>
        Muundo wa t-SNE wa seli za NK kwa kiwango cha seli moja kulingana na mchanganyiko wa RNA na uwakilishi wa protini. Seli zimepewa rangi na kuwekwa kwenye vipande kulingana na hali tofauti (NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK).
        <bold>
         b
        </bold>
        Uchambuzi wa vipengele vya msingi vya uwakilishi wa seli za NK zilizoathiriwa tofauti baada ya CITE-seq ya wadonaji wawili.
        <bold>
         c
        </bold>
        Uchanganuzi wa pamoja wa uwakilishi wa seli za NK kutoka kwa hali zote (muundo wa t-SNE kama (
        <bold>
         a
        </bold>
        )). Uchanganuzi wa Louvain kwenye matokeo ya PCA.
        <bold>
         d
        </bold>
        Wingi wa seli zinazohusiana na vikundi sita kama asilimia ya seli zote zilizopimwa.
        <bold>
         e
        </bold>
        Wingi wa seli zinazohusiana na vikundi 6 kama sehemu ya chembe za NK. Kwa kila chembe ya seli za NK (NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK), uwiano wa jumla wa vikundi hivi unajumlisha hadi moja.
        <bold>
         f
        </bold>
        Alama za usemi wa jeni au kipengele cha protini kwa kila kikundi. Vitu vya jeni na protini vimepangwa kulingana na kazi (Wadhibiti wa Kuzuia &amp; Wadhibiti, Mawasiliano ya TCR ya Chini, Kuimarika kwa Limfociti, Seli za NK Zimekoma). Kila nukta inawakilisha jeni au kipengele cha protini. Alama ya usemi wa kipengele X katika kikundi Y ni wastani wa usemi wa kipengele X kwa seli zote katika kikundi Y ikigawanywa na wastani wake kwa seli zote katika vikundi vyote vingine (isipokuwa kikundi Y, kinachoonyeshwa kama log10). Alama zaidi ya sifuri inaonyesha kuimarishwa kwa kipengele mahususi katika kikundi fulani ikilinganishwa na vikundi vingine. Mraba meusi unaonyesha wastani wa alama za usemi wa vipengele vyake (takwimu ni wastani wa jeni).
        <bold>
         g
        </bold>
        Kupanga jeni na protini kulingana na kazi yake. Maelezo ya kila kundi na vipengele vinavyohusiana navyo yanatolewa.
        <bold>
         a
        </bold>
        ,
        <bold>
         c
        </bold>
        –
        <bold>
         f
        </bold>
        Uchambuzi wa mwakilishi wa seli kutoka kwa mdonaji D1.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig3_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec5">
    <title>
     Ufutaji wa kingo ya kinga ya NKG2A huongeza shughuli ya anti-AML ya seli za CAR33-NK kwenye majaribio ya ndani
    </title>
    <p id="Par11">
     Ili kubaini kama kupungua kwa usemi wa NKG2A kwenye uso wa seli za CAR33-NK, ambazo kwa kiasi kikubwa ziliendelea na hali yao ya kuhamasishwa na utayari (Figs.
     <xref ref-type="fig" rid="Fig2">
      2
     </xref>
     ,
     <xref ref-type="fig" rid="Fig3">
      3
     </xref>
     ), itasababisha kuongezeka kwa uwezo wa kutekeleza kazi za seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK, tuliichambua uwezo wao wa kuua seli za AML zinazoonyesha HLA-E na CD33, kama vile seli za AML za mstari wa seli za OCI-AML2 na seli za msingi za mgonjwa za AML (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4a
     </xref>
     na
     <xref ref-type="supplementary-material" rid="MOESM1">
      S5
     </xref>
     ). Kwa kweli, seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zilionyesha uwezo wa juu wa kutekeleza kazi za kuua seli za AML kwa uwiano tofauti wa kutekeleza kazi za seli za NK kwa seli za AML, ikilinganishwa na seli za NT-,
     <italic>
      KLRC1
     </italic>
     - au CAR33-NK katika majaribio ya kuua seli za AML kwa muda mfupi (saa 4) na muda mrefu (saa 24) (Fig.
     <xref ref-type="fig" rid="Fig4">
      4a
     </xref>
     ) pamoja na uchanganuzi wa seli za maisha ya muda mrefu (Fig.
     <xref ref-type="fig" rid="Fig4">
      4b, c
     </xref>
     ). Uwezo ulioongezeka wa kutekeleza kazi za kuua seli za AML za seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK ulionyesha zaidi katika uchunguzi wa IncuCyte wa saa 24, ambapo ujumuishaji wa seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK na seli za AML za OCI-AML2 zinazoonyesha GFP (kijani) ulisababisha kuundwa kwa vikundi vya seli za AML zinazoonyesha Annexin V (nyekundu), ambazo zilionekana kwa wingi mdogo wakati seli za AML za OCI-AML2 zilipojumuishwa na seli za NT-NK (picha za kawaida Fig.
     <xref ref-type="fig" rid="Fig4">
      4c
     </xref>
     , Supplementary Movies
     <xref ref-type="supplementary-material" rid="MOESM4">
      1
     </xref>
     –
     <xref ref-type="supplementary-material" rid="MOESM8">
      5
     </xref>
     ). Ili kuchunguza kama hali ya kuhamasishwa ya seli za CAR33- na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK ilihusiana na kuongezeka kwa uzalishaji wa perforin/granzyme na kuchochea ishara za apoptotiki katika seli za AML, uchanganuzi wa western blot wa caspases katika seli za AML za OCI-AML2 zilizosalia na zilizochaguliwa baada ya kuunganishwa na seli za NK ulifanywa. Tuliiona kuongezeka kwa Caspase-3 na Caspase-9 kugawanyika katika seli za AML za OCI-AML2 ambazo zilisalia baada ya kukutana na seli za CAR33- na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK, ikionyesha kuchochea kwa kufa kwa seli kwa njia ya caspase (Fig.
     <xref ref-type="fig" rid="Fig4">
      4d
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4a, b
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
     </sup>
     . Uchanganuzi wa qPCR wa seli za NK ulionyesha kuongezeka kwa usemi wa granzyme B katika seli za CAR33- na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK baada ya saa 2 za kuunganishwa na seli za AML za OCI-AML2 (Fig.
     <xref ref-type="fig" rid="Fig4">
      4e
     </xref>
     ). Seli za
     <italic>
      KLRC1
     </italic>
     - na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zilichaguliwa kwa seli zisizo na NKG2A ili kubaini kama zingekuwa na uwezo wa juu wa kutekeleza kazi za kuua seli za AML. Kama udhibiti, seli za
     <italic>
      KLRC1
     </italic>
     - na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zilichaguliwa kwa seli zinazoonyesha CD56 ili kuepuka athari za kuchagua. Katika majaribio ya kuua seli za AML kwa muda mfupi (saa 4) na muda mrefu (saa 24), seli zilizochaguliwa zisizo na NKG2A,
     <italic>
      KLRC1
     </italic>
     - na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK hazionyesi uwezo wa juu wa kuua seli za AML za OCI-AML2 ikilinganishwa na mchanganyiko wa seli za
     <italic>
      KLRC1
     </italic>
     -NK usio na uchaguzi na takriban 50% seli zisizo na NKG2A, ikionyesha kwamba kupungua kwa 50% kwa usemi wa NKG2A kungekuwa kikubwa cha kutosha kufuta mhimili unaodhibiti wa NKG2A-HLA-E (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4c
     </xref>
     )
     <sup/>
     .
     <fig id="Fig4" position="float">
      <label>
       Fig. 4
      </label>
      <caption xml:lang="sw">
       <title>
        Ufutaji wa kijeni kizuia cha NKG2A (
        <italic>
         KLRC1
        </italic>
        ) huongeza shughuli za anti-AML za chembe za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK katika majaribio ya maabara.
       </title>
       <p>
        <bold>
         a
        </bold>
        Majaribio ya kuua kwa muda mfupi (saa 4) na muda mrefu (saa 24) kwa kutumia flow cytometry ya chembe za NK dhidi ya seli za CD33
        <sup>
         +
        </sup>
        /HLA-E
        <sup>
         +
        </sup>
        za OCI-AML2 kwa viwango tofauti vya E:T (
        <italic>
         n
        </italic>
        = 5). Maana ± SD.
        <bold>
         b
        </bold>
        Ufuatiliaji wa kuua kwa chembe za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK kwa kutumia kifaa cha IncuCyte-S3. Chembe za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK zilikuwa zikijumuishwa na seli za GFP
        <sup>
         +
        </sup>
        za OCI-AML2 kwa saa 26.5 na utoaji wa fluorescence ulipimwa kwa wakati (hali ya seli za OCI-AML2 pekee
        <italic>
         n
        </italic>
        = 3; nyingine
        <italic>
         n
        </italic>
        = 4). Wastani + anuwai.
        <bold>
         c
        </bold>
        Picha zinazoonyesha matokeo ya uchunguzi wa IncuCyte baada ya saa 24.5 ya chembe za NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK zilizojumuishwa na seli za GFP
        <sup>
         +
        </sup>
        za OCI-AML2 (E:T = 0.5:1). Seli za tumor zinazoishi zinaonyeshwa kwa rangi ya kijani kulingana na usemi wao wa GFP. Seli za tumor zilizooza zimepewa lebo nyekundu kwa kutumia Annexin V. Kwa ajili ya upigaji picha, jukwaa la IncuCyteS3 lilitumika.
        <bold>
         d
        </bold>
        Uchunguzi wa kugawanyika kwa caspase katika seli za OCI-AML2 zilizosalia na kugawanywa baada ya kuunganishwa na chembe za NK kwa saa 2 kwa kutumia western blot (jaribio moja linalowakilisha 3 limeonyeshwa; “clvd” = “imegawanyika”, “ctrl” = “udhibiti”).
        <bold>
         e
        </bold>
        Uchambuzi wa usemi wa jeni wa qPCR wa chembe za NT-,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -, CAR33- na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK baada ya kuunganishwa na seli za OCI-AML2 kwa saa 2 (E:T = 3:1) (
        <italic>
         n
        </italic>
        = 5). Maana ya mara tatu ya majaribio ya kiufundi ± SD. Uchambuzi wa takwimu ulifanywa kwa kutumia ANOVA ya njia mbili (
        <bold>
         a
        </bold>
        ), jaribio la t la mwanafunzi (
        <bold>
         b
        </bold>
        ), Wilcoxon iliyopangwa (
        <bold>
         e
        </bold>
        ). Kipengele cha
        <italic>
         n
        </italic>
        ni nakala za kibaolojia (kutoka kwa wadonaji wa afya tofauti) (
        <bold>
         a
        </bold>
        ,
        <bold>
         b
        </bold>
        ,
        <bold>
         e
        </bold>
        ).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig4_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     HLA-E ni lengo linalowekwa kwa njia sawa katika wagonjwa wa AML na seli za CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK zilionyesha uwezo wa kuua zaidi dhidi ya seli za msukosuko za wagonjwa wa nje
    </title>
    <p id="Par12">
     Ili kuchunguza kama seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zilizo na knockout ya NKG2A zina ufanisi ulioimarishwa dhidi ya nyenzo za mgonjwa, seli za mkojo ya mguu (BMCs) zilizotolewa kutoka kwa wagonjwa 10 tofauti wa AML wenye uvamizi mkubwa wa blast (&gt;90% CD45 AML blasts) zilijumuishwa kwa saa 4 na seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zilizotengenezwa kutoka kwa wadonaji tofauti wa afya (jumla ya
     <italic>
      n
     </italic>
     = 20 mchanganyiko tofauti wa wadonaji, Fig.
     <xref ref-type="fig" rid="Fig5">
      5a
     </xref>
     ). Tuliona kwamba HLA-E imeonyeshwa kwa wingi kwa wagonjwa wa AML bila uhusiano mkubwa kati ya vikundi tofauti (kundi
     <italic>
      n
     </italic>
     = 177, Fig.
     <xref ref-type="fig" rid="Fig5">
      5b–d
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
     </sup>
     . Usemi wa HLA-E haikuamua uwezekano wa kuishi kwa jumla (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S5a
     </xref>
     ). Seli zote za BMC za mgonjwa wa AML zilithibitishwa kwa uchanganuzi wa mtiririko wa damu kwa ujumuishaji wa CD33 na HLA-E (mchango wa kawaida unaonyeshwa katika Fig.
     <xref ref-type="fig" rid="Fig5">
      5e
     </xref>
     ; mkakati wa kuchagua Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S5b
     </xref>
     )
     <sup/>
     .
     <fig id="Fig5" position="float">
      <label>
       Fig. 5
      </label>
      <caption xml:lang="sw">
       <title>
        HLA-E ni lengo linalowekwa kwa njia moja katika wagonjwa wa AML na seli za NK za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        zinaonyesha uwezo wa kuua zaidi dhidi ya seli za AML zilizotolewa na wagonjwa ex vivo.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mfumo wa utayarishaji wa wagonjwa wa AML na ujumuishaji wao na seli za NK za mzunguko mmoja wa damu, kisha kufuatilia utendakazi wa seli za AML zilizouawa.
        <bold>
         b
        </bold>
        Mwonekano wa rangi ya viwango vya mabadiliko (CV). Kila nukta ni CV ya protein iliyopangwa kwa mpangilio wa kupanda. HLA-E imeangaziwa.
        <bold>
         c
        </bold>
        Mwonekano wa PCA wa vipengele viwili vya kwanza vimepewa rangi kulingana na kiwango cha HLA-E. Kila nukta ni sampuli.
        <bold>
         d
        </bold>
        Mwonekano wa joto wa maadili yaliyorekebishwa kutoka kwa jaribio la Kruska-Wallis lisilo la kimatibabu linalolinganisha kiwango cha HLA-E katika makundi: AML ya awali (ya awali dhidi ya ya pili dhidi ya ya matibabu, adj.
        <italic>
         p
        </italic>
        -thamani = 1.0), NPM1 (iliyobadilishwa dhidi ya aina ya asili, adj.
        <italic>
         p
        </italic>
        -thamani = 1.0), FLT3 (ITD dhidi ya TKD dhidi ya aina ya asili, adj.
        <italic>
         p
        </italic>
        -thamani = 1.0), FAB (MO hadi M7, adj.
        <italic>
         p
        </italic>
        -thamani = 1.0), Kundi la umri (&lt;50 dhidi ya 50-65 dhidi ya &gt;65, adj.
        <italic>
         p
        </italic>
        -thamani = 1.0), ELN 2017 (inayofaa dhidi ya ya wastani dhidi ya mbaya, adj.
        <italic>
         p
        </italic>
        -thamani = 1.0), Jinsia (mwanamke dhidi ya mwanamme, adj.
        <italic>
         p
        </italic>
        -thamani = 0.37).
        <bold>
         e
        </bold>
        Usemi wa CD33, usemi wa HLA-E na usemi wa CD45
        <sup>
         dim
        </sup>
        wa AML-blast katika sampuli moja ya kawaida ya BMC ya mgonjwa wa AML siku moja baada ya kufutwa (siku moja kabla ya kuzamishwa na seli za NK) zilionyeshwa kwa kutumia flow cytometry.
        <bold>
         f
        </bold>
        ,
        <bold>
         g
        </bold>
        Jaribio la kuua kwa saa 4 la seli za NK dhidi ya nyenzo za AML za wagonjwa (
        <bold>
         f
        </bold>
        ) na nyenzo za wagonjwa wenye vikundi vya molekuli vya hatari kubwa (
        <bold>
         g
        </bold>
        ). Kwa sababu ya viwango vya juu vya kuua kwa kuzingatia nyenzo za wagonjwa baada ya kufutwa, uuaaji maalum wa seli za AML zilizo na maisha unaoonyeshwa. Maana ya nakala za kiufundi za uuaaji wa seli za AML kwa wadonor tofauti wa seli za NK (Mdonor 1-20) wanaoonyeshwa kwa kila mgonjwa wa AML #1–10 (
        <bold>
         f
        </bold>
        ,
        <bold>
         g
        </bold>
        ).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig5_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par13">
     CAR33-
     <italic>
      KLRC1
     </italic>
     -NK seli zilionyesha uharibifu ulioboreshwa kwa masharti yote na wagonjwa waliosalinganishwa na NT-,
     <italic>
      KLRC1
     </italic>
     - au CAR33-NK seli dhidi ya seli za AML za mablasti kutoka kwa wagonjwa wote (Fig.
     <xref ref-type="fig" rid="Fig5">
      5f, g
     </xref>
     , jumla
     <italic>
      n
     </italic>
     = 10). Hii pia ni kweli kwa seli za mablasti zinazotokana na wagonjwa wenye vikundi vya molekuli vya hatari kubwa (Fig.
     <xref ref-type="fig" rid="Fig5">
      5g
     </xref>
     , Jedwali la Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     ,
     <italic>
      n
     </italic>
     = 6)
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec7">
    <title>
     Uchambuzi wa CITE-seq wa seli za CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK ulionyesha hali ya kuwashwa iliyohifadhiwa na shughuli iliyopunguzwa ya mzunguko wa seli baada ya kuwasiliana na AML
    </title>
    <p id="Par14">
     Matokeo yetu ya awali yanaonyesha kwamba kuanzishwa kwa CAR33 kwa pamoja na knockout ya reseptori ya kizuizi NKG2A kwa njia ya ushirikiano huimarisha uwezo wa kuua seli za NK bila kusababisha mabadiliko makubwa ya usemi wa jeni au alama za uso katika vijisehemu vya seli. Ili kuchunguza kama uwezo wa kuua seli za AML ulioboreshwa unaweza kuakisiwa katika mabadiliko ya kifenotipia ya vijisehemu vya seli za NK baada ya kukutana na seli za AML, tulifanya uchambuzi wa CITE-seq wa seli za NK zilizobadilishwa na za kazi (data ya cytotoxicity inaonyeshwa katika Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4d
     </xref>
     ) baada ya kuzamishwa kwa saa 2 na seli za OCI-AML2 (E:T = 1:1). Seli za NK zilitengwa kutoka kwa seli za AML za GFP kwa kutumia utengano wa seli kwa kutumia flow cytometer. Kama ilivyoelezwa awali kwa uchanganuzi wa CITE-seq kabla ya kuzamishwa, seli za NT-NK zilitengwa kama GFP-,
     <italic>
      KLRC1
     </italic>
     -NK kama GFP/NKG2A-, CAR33-NK kama GFP/CAR- na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK kama GFP/NKG2A/CAR (Fig.
     <xref ref-type="fig" rid="Fig6">
      6a
     </xref>
     ). Wakati data ya usemi wa seli za NK baada ya kuzamishwa zililinganishwa na zile za kabla ya kuzamishwa, tuligundua muundo wa kawaida wa mabadiliko ya usemi wa jeni na alama za uso ambayo ilisababishwa katika vijisehemu vyote vya seli za NK (Fig.
     <xref ref-type="fig" rid="Fig6">
      6b, c
     </xref>
     ). Ongezeko kubwa zaidi la usemi baada ya kukutana na seli za leukemic iligunduliwa kwa sitokini na chemokini, kama
     <italic>
      CSF2, CCL3
     </italic>
     ,
     <italic>
      CCL4
     </italic>
     , na TNF, kwa viwango vya udhibiti wa majibu ya kinga, kama
     <italic>
      IL3, IL1RN
     </italic>
     , CD69, na CD81, pamoja na viwango vya udhibiti wa usakinishaji, kama
     <italic>
      MYC
     </italic>
     <bold>
      (
     </bold>
     Fig.
     <xref ref-type="fig" rid="Fig6">
      6b
     </xref>
     ). Viwango vya usemi vya
     <italic>
      FCGR3A
     </italic>
     /CD16 na
     <italic>
      TNFSF8
     </italic>
     vilipunguzwa baada ya kukutana na seli za AML katika vijisehemu vyote vya seli za NK (Fig.
     <xref ref-type="fig" rid="Fig6">
      6b, c
     </xref>
     ). Mabadiliko haya ya usemi yaliyoletwa na kukutana na seli za AML yalikuwa kali zaidi katika seli za CAR33 na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK kuliko katika seli za NT na
     <italic>
      KLRC1
     </italic>
     -NK, mtawalia, ambayo inalingana na shughuli kubwa zaidi ya kuua ya vijisehemu hivi vya seli (Fig.
     <xref ref-type="fig" rid="Fig6">
      6c
     </xref>
     ). Seli za CAR33 na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK hazikuonyesha dalili za kuchoka kwa njia kama vile kuongezeka kwa viwango vya viambatisho vya kizuizi au pointi, kama
     <italic>
      HAVRC2
     </italic>
     (TIM3),
     <italic>
      TIGIT
     </italic>
     ,
     <italic>
      CD96
     </italic>
     ,
     <italic>
      PD-
     </italic>
     1 au
     <italic>
      CTLA-4
     </italic>
     kwa mstari na uchanganuzi wa qPCR baada ya saa 2 za kuzamishwa na seli za OCI-AML2 (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S6a
     </xref>
     )
     <sup/>
     .
     <fig id="Fig6" position="float">
      <label>
       Fig. 6
      </label>
      <caption xml:lang="sw">
       <title>
        Seli za NK za CAR33- na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        zinaonyesha hali iliyohifadhiwa ya kuchochea na miundo tofauti ya usemi wa jeni baada ya kuwasiliana na seli za AML.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mfumo wa utengenezaji wa seli za NK kwa uchambuzi wa seli moja baada ya kuzamishwa. Seli za NK za CAR zilizo na CAR
        <sup>
         +
        </sup>
        ,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK zilizo na NKG2A
        <sup>
         -
        </sup>
        na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK zilizo na CD33
        <sup>
         +
        </sup>
        /NKG2A
        <sup>
         -
        </sup>
        baada ya kuzamishwa kwa saa 2 na seli za OCI-AML2.
        <bold>
         b
        </bold>
        Mabadiliko ya jumla ya maandishi (RNA) katika kundi zima la seli za NK baada ya kuzamishwa na seli za OCI-AML2. Mwonekano wa volcano kama katika Fig.
        <xref ref-type="fig" rid="Fig2">
         2
        </xref>
        <bold>
         b
        </bold>
        –
        <bold>
         d
        </bold>
        .
        <bold>
         c
        </bold>
        Mwonekano wa joto unaonyesha mabadiliko ya logarithm ya kigezo cha usemi wa jeni na protini zilizobainishwa tofauti baada ya kuwasiliana na seli za OCI-AML2 ikilinganishwa na kabla ya kuwasiliana katika kila kundi la seli za NK. Mabadiliko chanya ya logFC yanawakilisha kuongezeka kwa usemi wa jeni baada ya kuzamishwa ikilinganishwa na usemi wake kabla ya kuzamishwa.
        <bold>
         d
        </bold>
        Mfumo wa kujumuisha wa kujumuisha wa seli za kibinafsi kutoka kwa vikundi vyote vya seli za NK baada ya kuzamishwa (t-SNE umeonyeshwa). Mfumo wa Louvain wa matokeo ya PCA.
        <bold>
         e
        </bold>
        Mwonekano wa nukta unaonyesha usemi wa jeni na alama za uso wa masilahi kwenye vikundi 6 vya seli za NK baada ya kuzamishwa na seli za OCI-AML2. Mwonekano wa rangi: kipimo cha kawaida ni wastani wa thamani zilizobadilishwa za usemi.
        <bold>
         f
        </bold>
        Wingi wa seli zinazohusika katika vikundi 6 kama sehemu ya vikundi vya seli za NK baada ya kuzamishwa. Kwa kila kundi la seli za NK (NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK), wingi wa seli zinazohusika katika vikundi vyote huongeza hadi moja.
        <bold>
         g
        </bold>
        Maadili ya usemi ya
        <italic>
         IFNG
        </italic>
        ,
        <italic>
         TOP2A
        </italic>
        na
        <italic>
         AURKB
        </italic>
        yanalinganishwa kati ya hali 4 (NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK) ya vikundi tofauti vya seli za NK kabla na baada ya kuzamishwa na seli za OCI-AML2.
        <bold>
         h
        </bold>
        Mwonekano wa joto unaonyesha mabadiliko ya logarithm ya
        <italic>
         IFNG
        </italic>
        ,
        <italic>
         TOP2A
        </italic>
        na
        <italic>
         AURKB
        </italic>
        na protini baada ya kuwasiliana na seli za OCI-AML2 ikilinganishwa na kabla ya kuwasiliana na seli za NK katika kila kundi la seli za NK (kama
        <bold>
         c
        </bold>
        ).
        <bold>
         i
        </bold>
        Kiwango cha INF-γ katika utakaso wa saa 4 za kuzamisha seli za NK na seli za OCI-AML2 (
        <italic>
         n
        </italic>
        = 3, nakala za kibaolojia kutoka kwa wadonor wa damu tofauti).
        <bold>
         j
        </bold>
        Uchambuzi wa usemi wa alama za uso za seli za NK baada ya saa 24 za kuzamishwa na seli za tumor ya AML zilimepimwa kwa kutumia flow cytometry (
        <italic>
         n
        </italic>
        = 3 wadonor). Maana ± SD. (
        <bold>
         b
        </bold>
        ) inaonyesha data iliyojumuishwa kwa wadonor D1 na D2. (
        <bold>
         c
        </bold>
        –
        <bold>
         g
        </bold>
        ) zinaonyesha uchanganuzi wa mwakilishi wa seli kutoka kwa mdonoro D1. Uchambuzi wa takwimu ulifanywa kwa kutumia jaribio la t la mwanafunzi jozi (
        <bold>
         i
        </bold>
        ) na ANOVA ya njia mbili (
        <bold>
         j
        </bold>
        ).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig6_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par15">
     Kisha tuchambue muundo wa seli za kibinafsi za vijisehemu tofauti vya seli za NK baada ya kuzamishwa na seli za AML ili kujifunza tofauti za mabadiliko ya kuhamasishwa kwa seli za NK. Vile vile na tulivyoona katika vijisehemu vya seli za NK kabla ya kuzamishwa, muundo wa
     <italic>
      KLRC1
     </italic>
     -NK ulifanana na ule wa NT-NK na muundo wa CAR33-NK ulikuwa zaidi unaofanana na ule wa CAR33-
     <italic>
      KLRC1
     </italic>
     -NK (Fig.
     <xref ref-type="fig" rid="Fig6">
      6d
     </xref>
     ). Wakati sampuli hizi za seli zilipangwa kulingana na sifa zao za jeni na alama za uso, tuligundua kwamba vikundi vya usakinishaji vya jeni vilivyo na viwango vya juu zaidi vya jeni zinazosababishwa na kuzamishwa, kama
     <italic>
      CCL4, CCL3, IFNG, TNF
     </italic>
     , na
     <italic>
      MYC
     </italic>
     (Fig.
     <xref ref-type="fig" rid="Fig6">
      6d–f
     </xref>
     , kundi 1 na 4), vilikuwa na wingi mkubwa katika seli za CAR33-NK na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK ikilinganishwa na vijisehemu vingine vya seli za NK. Wingi mkubwa zaidi ya seli hizi zinazotoa IFN-γ (kundi la usakinishaji 1), na hivyo viwango vya juu zaidi vya IFN-γ katika mabaki ya kuzamisha kwa saa 4 ziliona katika seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK baada ya kuzamishwa (Fig.
     <xref ref-type="fig" rid="Fig6">
      6e–i
     </xref>
     ) ikilinganishwa na seli za CAR33-NK, kwa mstari na ugunduzi kwamba kundi hili la seli lilisababisha uwezo wa kuua mkubwa zaidi
     <sup/>
     .
    </p>
    <p id="Par16">
     Zaidi ya tofauti katika usemi wa IFN-γ, tuligundua kuwa seli zinazotoa jeni zinazohusiana na mzunguko wa seli (DNA topoisomerase II alpha (
     <italic>
      TOP2A
     </italic>
     ), aurora kinase B (
     <italic>
      AURKB
     </italic>
     ) na
     <italic>
      TYMS
     </italic>
     , Fig.
     <xref ref-type="fig" rid="Fig6">
      6e–h
     </xref>
     , kundi la usakinishaji 2) zilikuwa na wingi mkubwa katika seli za CAR33-NK ambazo hazikuwa na knockout ya
     <italic>
      KLRC1
     </italic>
     . Pamoja na ukweli kwamba kuzamishwa na seli za AML kusababisha kupungua kwa jumla kwa usemi wa jeni zinazohusiana na mzunguko wa seli (Fig.
     <xref ref-type="fig" rid="Fig6">
      6h
     </xref>
     ), tulifanikiwa kufanya uchunguzi wa kiwango cha juu cha kuzaliana kwa seli za CAR33-NK ikilinganishwa na seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK baada ya kukutana na seli za AML kwa viwango tofauti vya kuzaliana kwa mzunguko wa seli (mchanga mmoja anayewakilisha wagonjwa wote unaonyeshwa katika Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S6b
     </xref>
     ). Kwa kiwango cha kifenotipia, tuligundua hali ya kuhamasishwa zaidi baada ya kuzamishwa kwa saa 24 na seli za OCI-AML2 kwa alama za kuhamasishwa CD69 na viwango vya juu vya usemi vya DNAM1, NKG2D (Fig.
     <xref ref-type="fig" rid="Fig6">
      6j
     </xref>
     ). Idadi kubwa ya seli za NK zilionekana kuwa zinaonyesha pointi za kinga kama vile PD-1 na TIM-3, na seli za CAR33-NK na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zilionyesha kuongezeka kwa usemi wa TIGIT baada ya kukutana na seli za AML (Fig.
     <xref ref-type="fig" rid="Fig6">
      6j
     </xref>
     )
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec8">
    <title>
     Idadi ndogo ya seli za CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK zinaweza kuangamiza seli za kuanzisha ukimwi zilizopo kwenye mafupa
    </title>
    <p id="Par17">
     <fig id="Fig7" position="float">
      <label>
       Fig. 7
      </label>
      <caption xml:lang="sw">
       <title>
        Seli za NK za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        zenye viwango vya chini katika muundo wa xenograft wa OCI-AML2 wa NSG-SGM3 unaonyesha ufanisi ulioimarishwa ikilinganishwa na
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK au CAR33-NK.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mfumo wa tathmini ya maisha ya matibabu ya mara tatu ya seli za NK za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        (mara tatu na 5 × 10
        <sup>
         6
        </sup>
        seli kwa njia ya vena) pamoja na matibabu ya chini ya ngozi ya IL-2 katika muundo wa xenograft wa OCI-AML2 (Luc
        <sup>
         +
        </sup>
        ) wa NSG-SGM3.
        <bold>
         b
        </bold>
        Picha za BLI za panya tofauti zilizotibiwa na OCI-AML2 (Luc
        <sup>
         +
        </sup>
        ) zilizotumwa kwa muda (
        <italic>
         n
        </italic>
        = 4–9). Panya walipokea matibabu ya mara tatu ya 5 × 10
        <sup>
         6
        </sup>
        seli za NK siku 3, 7 na 10 baada ya kuzamishwa kwa seli za AML.
        <bold>
         c
        </bold>
        Uchambuzi wa jumla wa mtiririko (foton kwa pili) wa panya (
        <italic>
         n
        </italic>
        = 4–9). Maana ± SD.
        <bold>
         d
        </bold>
        Kuishi na mizigo ya seli za AML ya panya zilizotumwa na OCI-AML2 zilionyeshwa kwa siku 36.
        <bold>
         e
        </bold>
        Mfumo wa tathmini ya matibabu ya mara mbili ya seli za NK za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        (mara mbili na 3 × 10
        <sup>
         6
        </sup>
        seli kwa njia ya vena) pamoja na matibabu ya chini ya ngozi ya IL-2 katika muundo wa xenograft wa OCI-AML2 (Luc
        <sup>
         +
        </sup>
        ) wa NSG-SGM3.
        <bold>
         f
        </bold>
        Picha za BLI za panya tofauti zilizotibiwa na OCI-AML2 (Luc
        <sup>
         +
        </sup>
        ) zilizotumwa kwa muda (
        <italic>
         n
        </italic>
        = 3–4). Panya walipokea matibabu ya mara mbili ya 3 × 10
        <sup>
         6
        </sup>
        seli za NK siku 3 na 10 baada ya kuzamishwa kwa seli za AML.
        <bold>
         g
        </bold>
        Uchambuzi wa jumla wa mtiririko (foton kwa pili) wa panya (
        <italic>
         n
        </italic>
        = 3–4). Maana ± SD.
        <bold>
         h
        </bold>
        Mfumo wa jaribio la kuzamisha upya wa tishu za mafuta (BM). Seli za BM za wanyama waliochukuliwa na seli za NK (hapo awali wasio na matibabu, NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK) zilitolewa siku 18, zilijumuishwa, na kuzamishwa kwenye panya mpya wa NSG-SGM3 (5 × 10
        <sup>
         6
        </sup>
        seli/kiboko;
        <italic>
         n
        </italic>
        = 2–6).
        <bold>
         i
        </bold>
        Kuishi na mizigo ya seli za AML ya panya zilizotumwa na BM zilionyeshwa kwa siku 120 (mpango wa majaribio ya wanyama: mwisho wa jaribio).
        <bold>
         j
        </bold>
        Uchanganuzi wa kawaida wa microskopia ya seli za AML za kijani kibichi katika historia ya BM siku 18 baada ya kuzamishwa kwa seli za AML. Uchambuzi wa takwimu ulifanywa kwa kutumia ANOVA ya njia mbili (
        <bold>
         c
        </bold>
        ,
        <bold>
         g
        </bold>
        ) na Kaplan-Meier (Jaribio la Log-rank (Mantel-Cox)) (
        <bold>
         d
        </bold>
        ,
        <bold>
         i
        </bold>
        ).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig7_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
  </sec>
  <sec id="Sec9" sec-type="discussion">
   <title>
    Jadiliano
   </title>
   <p id="Par18">
    Utumiaji wa kimatibabu wa seli za awali za CAR-NK ni mbinu inayowezekana ya matibabu ya seli ambayo ni salama na yenye ufanisi. Katika majaribio ya kimatibabu ya Vipindi I/II, seli za awali za CAR-NK zilizoambatishwa na CD19 zilifikia viwango vya ahadi katika wagonjwa walio na magonjwa ya seli za B, pamoja na uwakilishi mzuri wa usalama bila kesi zilizoripotiwa za kutolewa kwa cytokine kali (CRS), neurotoxicity, au ugonjwa wa kugonga kwa mwenzi (GvHD)
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR35">
      35
     </xref>
    </sup>
    . Utumiaji wa seli za NK kwa ajili ya kuzalisha seli za CAR za utoaji huenda na manufaa yanayowezekana, hasa katika hali ya antijeni zinazolengwa ambazo hazijikita katika seli za saratani pekee, kama katika hali ya AML
    <sup>
     <xref ref-type="bibr" rid="CR36">
      36
     </xref>
    </sup>
    . Katika masomo ya kuongoza, matibabu ya kinga ya AML kwa kutumia seli za NK zisizobadilishwa zilihalalishwa kuwa salama, na majibu ya blast yalitazamwa katika baadhi ya wagonjwa
    <sup>
     <xref ref-type="bibr" rid="CR37">
      37
     </xref>
    </sup>
    . Hasa, idadi ya seli za NK zinazotokana na cytokine ina uwezo mkubwa wa kupambana na saratani ya damu, na jukumu muhimu kwa IL-15 au IL-12/15/18 inayotokana na kumbukumbu ya seli za NK
    <sup>
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
    </sup>
    . Hata hivyo, mazingira ya kudumisha kinga ya sehemu ya saratani katika mifupa na upinzani wa seli za saratani zinaweza kuzuia ufanisi wa matibabu ya seli. Uchambuzi wa seli moja imeripotiwa, ambao ulionyesha njia za tofauti za seli za NK katika mifupa na alama ya msongo katika AML, ambayo iliharibu kwa kiasi kikubwa utendaji wa seli za NK
    <sup>
     <xref ref-type="bibr" rid="CR38">
      38
     </xref>
     ,
     <xref ref-type="bibr" rid="CR39">
      39
     </xref>
    </sup>
    . Kwa muhimu, uwezo wa asili wa kupambana na tumor ya seli za NK una uwezo wa kuangamiza pia seli za tumor ambazo zimepoteza usemi wa antijeni ya CAR, ambayo bado haiwezekani katika matibabu ya seli za CAR-T
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
    </sup>
    . Zaidi ya hayo, viwango vya juu vya INF-γ vilivyotolewa vinaweza kudhoofisha utendaji wa kupambana na tumor ya seli za NK baada ya kuwasiliana na seli za tumor
    <sup>
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Viwango vya juu vya INF-γ vilivyotolewa pia vilionekana kwa seli za CAR-NK zinazolenga CD33 baada ya kuwasiliana na seli za AML, ambazo zinaweza kusababisha kuongezeka kwa molekuli za kudumisha kinga kama vile protini isiyo ya kawaida ya MHC I HLA-E
    <sup>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Kwa hiyo, ufanisi wa kupambana na AML unaweza kuzuiwa kwa njia ya viambatisho vya kinga vya kudumisha kinga kama vile NKG2A, ambayo huambatana na HLA-E, mara nyingi huongezeka kwenye seli za saratani
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
     ,
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     ,
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
    </sup>
    . Data za awali za kundi letu na wengine zilionyesha kuwa kuzuia HLA-E/NKG2A kunaweza kushindwa kwa njia ya kuzuia au kurekebisha NKG2A kwa kutumia CRISPR/Cas9
    <sup>
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Katika kazi hii, tunaelezea uundaji wa mafanikio wa seli za NK za aina mbili kwa kuchanganya uundaji wa CAR33 na uharibifu wa jeni ya
    <italic>
     KLRC1
    </italic>
    kwa kutumia CRISPR/Cas9. Seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zilizotokana zina uwezo wa kupambana na seli za CD33/HLA-E kama zile zilizo na CAR33-NK au
    <italic>
     KLRC1
    </italic>
    -NK dhidi ya mstari wa seli za AML, seli za AML za awali za mgonjwa zilizopatikana ex vivo na katika muundo wa xenograft wa AML in vivo
    <sup/>
   </p>
   <p id="Par19">
    Ufanisi wa usemi wa CD33-CAR baada ya kuambukizwa kwa lentiviral ulikuwa katika mstari na data zilizopita zilizoripotiwa na kundi letu na wengine
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     ,
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
     ,
     <xref ref-type="bibr" rid="CR40">
      40
     </xref>
     ,
     <xref ref-type="bibr" rid="CR41">
      41
     </xref>
    </sup>
    . Kwa kuzingatia, asilimia ya seli za NK chanya za CAR iliongezeka kwa wakati (Fig.
    <xref ref-type="fig" rid="Fig1">
     1c
    </xref>
    ), ambayo inaweza kuhusishwa na uteuzi wa promota
    <sup>
     <xref ref-type="bibr" rid="CR42">
      42
     </xref>
     ,
     <xref ref-type="bibr" rid="CR43">
      43
     </xref>
    </sup>
    . Uwezekano wa uharibifu wa jeni ya
    <italic>
     KLRC1
    </italic>
    kwa kutumia CRISPR/Cas9 usio na virusi ulikuwa wa juu na uchanganuzi wa usambazaji wa Indel ulionyesha kuongezeka kwa +1 na kufuata kwa −15 kutoondolewa katika kuwepo au kutokuwepo kwa CAR na kutoondolewa kwa −15 kinaweza kuelezewa na kuwepo kwa mfuatano wa micro-homology unaozunguka sehemu ya kukatwa (Fig.
    <xref ref-type="fig" rid="Fig1">
     1f
    </xref>
    , Supplementary Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     S1c
    </xref>
    ,
    <xref ref-type="supplementary-material" rid="MOESM1">
     1d
    </xref>
    ). Uchambuzi wa mfuatano wa kizazi (NGS) ulionyesha shughuli ndogo ya CRISPR/Cas9 nuclease katika seli za NK za CAR-KO kwa OT1 (~0.1%) ambayo ni sawa na ripoti za awali (Supplementary Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     S1c, d
    </xref>
    ). Hata hivyo, mbinu za jadi kama vile NGS zinaweza tu kugundua matukio yasiyotarajiwa ya genotoxic katika umbo dogo la insertions/deletions (INDELs) lakini hazizingatii mabadiliko ya jumla ya muundo wa jeni
    <sup>
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
     <xref ref-type="bibr" rid="CR42">
      42
     </xref>
    </sup>
    . Teknolojia mpya kama vile CAST-seq inaruhusu kugundua mabadiliko katika muundo wa jumla wa kromosomu na inapaswa kuthibitisha uchanganuzi wa jumla wa jeni, hata kama hatari ya mutagenesis ni ya chini kabisa katika seli zilizokamilika
    <sup>
     <xref ref-type="bibr" rid="CR44">
      44
     </xref>
     ,
     <xref ref-type="bibr" rid="CR45">
      45
     </xref>
    </sup>
    .
   </p>
   <p id="Par20">
    Kwa kuzingatia, ingawa uwezekano wa juu wa uharibifu wa jeni ya
    <italic>
     KLRC1
    </italic>
    (Fig.
    <xref ref-type="fig" rid="Fig1">
     1e
    </xref>
    ) ulifikiwa katika kiwango cha jeni, hii iliongezeka tu hadi kuzuiwa kwa NKG2A chanya kwa takriban 50% (Fig.
    <xref ref-type="fig" rid="Fig1">
     1d
    </xref>
    ). Tunadhani kuwa uondoaji mkubwa wa mfuatano wa −15 unaweza kuwa na jukumu katika athari hii. Uondoaji wa mfuatano wa amino tano unaweza kufuta utendaji wa NKG2A lakini si lazima usemi wake wa uso. Wakati kazi yetu ilionyesha kuwa idadi ya seli za NK zisizo na NKG2A 100% zilizosambazwa haziwezi kuongeza zaidi uwezo wa kupambana na magonjwa ya saratani katika vitro (Supplementary Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     S4c
    </xref>
    ), bado haijaeleweka kama kuzuiwa kwa NKG2A kwa kiwango kikubwa ni muhimu katika muktadha wa utendaji wa seli za NK, ambao unasimamiwa na usawa wa utendaji wa kuchochea na kudumisha kinga wa uso wa seli. Katika muktadha huu, ni muhimu kutambua kwamba usemi uliobaki wa NKG2A unaweza bado kuzuia shughuli za seli za CAR-NK katika vivo, kwa sababu ya uwezekano wa kuongezeka kwa HLA-E kwenye seli za tumor baada ya kuwasiliana na IFN-γ inayotolewa na seli za NK.
   </p>
   <p id="Par21">
    Katika kazi yetu ya awali ya utafiti, tulizalisha seli za awali za CAR33-NK zilizounganishwa na IL-2/15 ambazo zilionyesha shughuli kali za kupambana na magonjwa ya saratani ya CD33 AML katika vitro na katika muundo wa xenograft wa vivo
    <sup>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
    </sup>
    . Viwango vya juu vya IFN-γ vinaweza kusababisha kuongezeka kwa HLA-E kwenye seli za tumor, ambayo pia imeonekana baada ya matibabu ya seli za CAR33-NK katika wanyama walio na AML na pia katika seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK baada ya kuwasiliana na seli za AML katika vitro (Fig.
    <xref ref-type="fig" rid="Fig6">
     6g, i
    </xref>
    )
    <sup>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR46">
      46
     </xref>
    </sup>
    . Zaidi ya hayo, uchambuzi wa nyuma wa nyenzo za mgonjwa wa AML zilionyesha kuwa HLA-E inaonyeshwa kwa njia ya mara kwa mara kwenye seli za AML na haionekani kuwa na uhusiano na majibu ya kimatibabu (
    <italic>
     n
    </italic>
    = 177, Fig.
    <xref ref-type="fig" rid="Fig5">
     5b–d
    </xref>
    , Supplementary Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     S5a
    </xref>
    ). Uchunguzi huu unasisitiza umuhimu wa kimatibabu wa mhimili wa HLA-E/NKG2A na kufungua dhana ya uhariri wa seli za NK ili kushinda kinga hii ya kudumisha kinga. Pamoja na matibabu yanayoweza kusaidia wagonjwa walio na aina mbaya za saratani ya damu kwa njia ya upandikizaji wa seli za mkojo za mwenzi, kurudia kwa ugonjwa bado ndio sababu kuu ya kifo na matibabu mbadala yanahitajika
    <sup>
     <xref ref-type="bibr" rid="CR47">
      47
     </xref>
     ,
     <xref ref-type="bibr" rid="CR48">
      48
     </xref>
    </sup>
    . Katika mwelekeo huu, utayarishaji wa seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK kutoka kwa wadonaji tofauti ulisababisha uwezo wa kupambana na magonjwa ya saratani ulioongezeka kwa wingi dhidi ya seli za AML za awali za mgonjwa (HLA-E) zilizopatikana kutoka kwa kundi la wagonjwa walio na aina za molekuli za hatari za juu au za kawaida (Fig.
    <xref ref-type="fig" rid="Fig5">
     5f, g
    </xref>
    )
    <sup>
     <xref ref-type="bibr" rid="CR30">
      30
     </xref>
    </sup>
    .
   </p>
   <p id="Par22">
    Kwa lengo la kuchunguza zaidi mbinu zinazosababishwa na uhariri maalum wa jeni, tulifanya uchanganuzi wa seli moja ya utendakazi wa seli za NK zilizobadilishwa na CRISPR/Cas9. Baada ya kuwasiliana moja kwa moja na seli za AML, ongezeko la utendakazi wa chini wa CAR, na kuongezeka kwa alama za kuchochea na kuhamia zilionekana hasa katika idadi ya seli za CAR33- na CAR33-
    <italic>
     KLRC1
    </italic>
    -NK, ambayo inaweza kueleza uharibifu ulioongezeka wa seli za AML. Zaidi ya hayo, uchanganuzi wa CITE-Seq ulionyesha alama ya utendakazi wa IFN-γ Type-I inayotambulika kama inayopatikana hasa katika seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK baada ya kuwasiliana na AML. Hii inalingana na utafiti mwingine wa hivi punde unaoonyesha kuchochea kwa IFN-γ baada ya kuwasiliana na aina mbalimbali za saratani ya damu
    <sup>
     <xref ref-type="bibr" rid="CR39">
      39
     </xref>
    </sup>
    .
   </p>
   <p id="Par23">
    Kwa kweli, wakati wa kulinganisha bidhaa ya CAR33-
    <italic>
     KLRC1
    </italic>
    -NK katika majaribio ya kimatibabu ya saa 4 na 24 dhidi ya seli za OCI-AML2, seli za CAR33-NK zilionekana kuwa na uwezo wa kuua muda mfupi unaosukumwa na ongezeko la caspase-3 na kuachilia perforin na granzyme, wakati seli za
    <italic>
     KLRC1
    </italic>
    -NK zilikuwa na uwezo wa kuongezeka kwa mchakato wa muda mrefu (Fig.
    <xref ref-type="fig" rid="Fig4">
     4
    </xref>
    ). Muhimu, seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zinapata manufaa kutokana na urekebishaji wa ziada, hasa kwa uwiano wa chini wa E:T, ambao unawakilisha hali zinazowezekana za kibayolojia katika binadamu (Figs.
    <xref ref-type="fig" rid="Fig5">
     5
    </xref>
    ,
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    )
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR48">
      48
     </xref>
     ,
     <xref ref-type="bibr" rid="CR49">
      49
     </xref>
    </sup>
    . Wakati data za CITE-Seq zinaonyesha kuwa seli za CAR33- na CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zinatumia mbinu zinazofanana za kuua, mchanganyiko wa kimatibabu ya muda mfupi na mrefu katika seli za NK zilizo na urekebishaji wa mara mbili huonekana kuwa inasimamiwa na CAR na kudumishwa kupitia udhibiti wa checkpoint ya NKG2A. Hii inaweza kuwa muhimu kwa ufanisi wa seli za NK katika mazingira ya tumor yenye IFN-γ/HLA-E ya juu
    <sup/>
    .
   </p>
   <p id="Par24">
    Majaribio yetu ya kibayolojia hayapendekezi dosi ya mwisho bora lakini yalithibitisha uwezo wa seli za NK zilizo na urekebishaji wa mara mbili kwa matibabu ya AML tayari kwa matumizi mawili ya dosi za chini za 3 × 10 seli za NK na ufanisi unaolingana baada ya mara tatu 5 × 10 seli za NK. Data za kimatibabu kutoka kwa majaribio ya hivi karibuni ya seli za CAR-NK kwa matibabu ya magonjwa ya seli za B tayari yameonyesha kuwa athari kubwa zinaweza kupatikana kwa dosi za chini za matibabu ya seli
    <sup>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    . Hata hivyo, hili linahitaji kuchunguzwa zaidi kwa matibabu ya seli za NK zilizo na urekebishaji wa mara mbili inayolenga AML kwenye njia ya kutafsiriwa kimatibabu.
   </p>
   <p id="Par25">
    Urekebishaji wa mara mbili wa seli za NK hutoa uwezo mkubwa wa bidhaa za seli za CAR-NK zilizoboreshwa ambazo pia zinaweza kustahimili njia za udhibiti wa kinga zinazotoa kinga zaidi ya NKG2A. Kwa mfano, hivi karibuni imeonekana kuwa kuondoa jeni ya cytokine-inducible Src homology 2–containing (
    <italic>
     CISH
    </italic>
    ) katika seli za CAR-NK zilizotokana na damu ya kamba za uzazi kunaweza kuboresha afya ya kimetaboliki, kudumu kwa muda mrefu kwa maisha na uwezo wa kuua
    <sup>
     <xref ref-type="bibr" rid="CR49">
      49
     </xref>
    </sup>
    . Hata hivyo, urekebishaji wa jeni wa viwango vya udhibiti wa kinga unahitaji kutathminiwa kwa uangalifu kwa ufanisi wao wa ziada.
   </p>
   <p id="Par26">
    Kuhusiana na umuhimu wa njia ya ishara ya TIGIT katika seli za NK, imeelezwa kuwa kuondoa TIGIT kunaweza kuboresha utendakazi wa seli za NK zisizo na urekebishaji lakini si za CAR-NK katika AML
    <sup>
     <xref ref-type="bibr" rid="CR50">
      50
     </xref>
    </sup>
    . Kinyume chake, athari iliyoboreshwa ya seli za NK zilizo na urekebishaji wa mara mbili za
    <italic>
     TIGIT
    </italic>
    -knockout-CAR-NK zimeonekana katika glioblastoma, ambayo inaendana kwa njia ya kushangaza na matokeo yetu kwa
    <italic>
     KLRC1
    </italic>
    ya seli za CAR-NK katika AML
    <sup>
     <xref ref-type="bibr" rid="CR51">
      51
     </xref>
    </sup>
    .
   </p>
   <p id="Par27">
    Katika tafsiri ya kimatibabu ya siku zijazo, mbinu ya urekebishaji wa jeni inakuwa muhimu zaidi, kwani magonjwa ya pili ya saratani yameonekana ambayo yanaweza kuwa yametokana na bidhaa za seli za CAR-T zilizotengenezwa kwa njia ya vimelea
    <sup>
     <xref ref-type="bibr" rid="CR52">
      52
     </xref>
    </sup>
    . Katika muktadha huu, mbinu za urekebishaji wa jeni zisizo na vimelea zinaweza kupunguza hatari ya ubadilishaji wa seli za saratani katika matibabu ya kinga ya seli za CAR
    <sup>
     <xref ref-type="bibr" rid="CR26">
      26
     </xref>
     ,
     <xref ref-type="bibr" rid="CR53">
      53
     </xref>
     ,
     <xref ref-type="bibr" rid="CR54">
      54
     </xref>
    </sup>
    .
   </p>
   <p id="Par28">
    Kwa ujumla, tumethibitisha kwa mara ya kwanza kwamba CAR33-
    <italic>
     KLRC1
    </italic>
    -NK seli zinawakilisha dhana ya matibabu ya seli ya NK yenye ubunifu ambayo inaweza kushinda ukingizwaji wa kinga ya AML na inaonekana kuwa na utendakazi wa hali ya juu na salama katika tathmini ya kimatibabu ya in vivo. Ubadilishaji wa kijeni mara mbili kwa kuanzisha CAR na kufuta kwa usahihi vipokezi vya kizuizi vya checkpoint ina uwezo wa kuruhusu seli za NK kuepuka athari za kudhibiti si tu za AML, bali pia uwezekano wa aina nyingi za saratani zingine
    <sup/>
    .
   </p>
  </sec>
  <sec id="Sec10" sec-type="methods">
   <title>
    Mbinu
   </title>
   <sec id="Sec11">
    <title>
     Ukadiriaji wa Maadili
    </title>
    <p id="Par29">
     Matazo yote yanayotumia nyenzo za binadamu yalidhidiwa na bodi ya maadili ya mahali hapo (idhini nambari 329/10 na 274/18) na yalifanywa kwa kufuata kanuni za Helsinki. Matumizi ya masi ya mifupa yalidhidiwa na Kamati ya Maadili ya Hospitali ya Chuo Kikuu cha Frankfurt (idhini Nambari SHN-12-2016, marekebisho 01 2021 na 02 2022) na muungano wa utafiti wa saratani ya damu (SAL, idhini Nambari EK98032010). Majaribio yote ya wanyama yalidhidiwa na Regierungspräsidium Darmstadt, Ujerumani (FK1123).
    </p>
   </sec>
   <sec id="Sec12">
    <title>
     Seli za AML za Awali
    </title>
    <p id="Par30">
     Seli za mgonjwa wa AML za awali zilizotolewa na BMC zilitolewa katika mazingira ya IMDM yenye 20% FBS na 1% penicillin/streptomycin na seli zilifungwa kwa dakika 10 na 100 µg/ml DNAse I. Kisha, seli zilifungwa na kuzalishwa katika mazingira ya IMDM yenye L-glutamine na HEPES (Invitrogen) yenye 100 U/ml penicillin, 100 mg/ml streptomycin, 100 ng/ml kichocheo cha seli za mizizi (SCF), 20 ng/ml IL-3, 20 ng/ml IL-6 na 100 ng/ml FMS-tyrosine kinase 3 ligand (FLT3L). Seli zilichaguliwa kwa kiwango cha seli cha 2×10 seli/ml katika sahani ya 12-well. Siku inayofuata seli zilichambuliwa kwa uhai kupitia umbo (FSC/SSC) na 7-AAD-staining (BD Biosciences), AML blasts zilihesabiwa kulingana na usemi wa CD45dim kwa kutumia anti-CD45-APC (Clone 2D1, BD Biosciences), usemi wa CD33 kwa kutumia anti-CD33-BV421 (Clone WM53, BD Bioscience) na usemi wa HLA-E kwa kutumia anti-HLA-E-APC (Clone 3D12, Biolegend) antibodies. Siku ya pili baada ya kutolewa, seli zilifungwa katika majaribio ya sumu ya seli za NK kwa saa 4. Kwa maelezo ya kina kuhusu sifa za wagonjwa, tazama Jedwali la Ziada la
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     <sup/>
     . Matumizi ya nyenzo za wagonjwa wa awali yalidhidiwa na Tume ya Maadili ya Hospitali ya Chuo Kikuu cha Frankfurt, Ujerumani (idhini nambari 274/18). Washiriki wote walitoa kibali chao kilichohifadhiwa kwa kuandikwa kwa kufuata Azimio la Helsinki.
    </p>
   </sec>
   <sec id="Sec13">
    <title>
     Utoaji wa Seli za NK
    </title>
    <p id="Par31">
     Seli za NK zilitengwa kutoka kwa mabaki ya damu ya wadonaji waliowekwa kwa ajili ya kuchangia damu (DRK-Blutspendedienst Baden-Württemberg-Hessen, Frankfurt am Main, Ujerumani) kama ilivyoelezwa hapo awali
     <sup>
      <xref ref-type="bibr" rid="CR55">
       55
      </xref>
     </sup>
     . Kwa ufupi, seli za mononukleari za damu za periferali (PBMCs) zilitengwa kwa centrifugation ya kugeuza Ficoll (Biocoll, Biochrom) na utajiri wa seli za NK ulifanywa kwa kutumia Kit ya Utajiri wa Seli za NK za Binadamu (StemCell) kwa kufuata maelekezo ya mtengenezaji. Uchafu wa seli za NK ulibainishwa kwa uchambuzi wa cytometry ya mtiririko. Mradi huu ulidhidiwa na Kamati ya Maadili ya Chuo Kikuu cha Goethe cha Frankfurt, Ujerumani (idhini nambari 329/10).
    </p>
   </sec>
   <sec id="Sec14">
    <title>
     Ukandaaji wa Seli za NK za Kijeni zilizoundwa kwa njia za kigeni
    </title>
    <p id="Par32">
     Seli za NK za awali kutoka kwa mabaki ya damu zilichangiwa kwa 300
     <italic>
      g
     </italic>
     kwa dakika kumi. Utando ulitolewa, na seli zilifungwa katika mazingira ya RPMI1640 yenye 20% serum ya fetusi ya ng'ombe (FBS). Kisha, kiasi sawa cha mazingira ya RPMI1640 yenye 20% Dimethyl sulfoxide (DMSO) yilitolewa kwa njia ya mvuke wakati wa kuchanganya mchanganyiko wa seli. Kiwango cha mwisho kilikuwa kati ya (4-16) × 10 seli/ml. Mchanganyiko wa seli ulifungwa kwa -80 °C kwa kutumia kontena ya kufungia ya Mr. Frosty (Thermo Fisher Scientific). Kwa ajili ya uhifadhi wa muda mrefu, seli zilitolewa kwenye nitrogeni ya kioevu
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec15">
    <title>
     Uundaji wa CAR na Uzalishaji wa Vekta ya Lentiviral
    </title>
    <p id="Par33">
     A second-generation CD33-targeting CAR ambayo inajumuisha mfuatano wa My96 scFv ulitumika kama ilivyoelezwa hapo awali
     <sup>
      <xref ref-type="bibr" rid="CR40">
       40
      </xref>
     </sup>
     . My96 scFv ilikuwa imeunganishwa na CD8 hinge na transmembrane domain, 4-1BB/CD137 co-stimulatory domain, na CD3ζ activation domain. Leader peptide ikijumuisha EF-1α-based promoter iliyotokana na GM-CSFRα iliongezwa. Self-inactivating baboon envelope-pseudotyped lentiviral vectors (third generation) zilitengenezwa kwa kutumia transient transfection kwenye HEK293T cells kwa kutumia MACSfectin (Miltenyi Biotec) au polyethylenimine (PEI)
     <sup>
      <xref ref-type="bibr" rid="CR56">
       56
      </xref>
      ,
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec16">
    <title>
     Uingizwaji wa Seli za NK za Awali
    </title>
    <p id="Par34">
     NK cells zilitolewa kama ilivyoelezwa hapo awali
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
     </sup>
     . Siku ya pili baada ya kutenga NK cells, cells zilitolewa na lentiviral particles kwa pamoja na Vectofusin-1 (Miltenyi Biotec; 2.5 µg/ml final concentration). Mchanganyiko wa virus-cells ulipinduliwa kwa 400
     <italic>
      g
     </italic>
     kwa saa 2 kwa 32 °C. Saa 24 baada ya kutolewa, nusu ya medium ilibadilishwa na medium mpya. Baada ya kutolewa, NK cells zilikuzwa katika NK-MACS medium iliyotolewa na 5% human plasma, 1% NK-MACS Supplements, 1% Pen/Strep, 500 IU/ml IL-2 (Miltenyi Biotec au Novartis) na 10 ng/ml IL-15 (Miltenyi Biotec) au 50 ng/ml IL-15 (CellGenix)
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec17">
    <title>
     <italic>
      KLRC1
     </italic>
     -kuishia CRISPR/Cas9
    </title>
    <p id="Par35">
     NK cells za awali zilitengenezwa kwa kutumia mfumo wa CRISPR/Cas9 usio na virus kama ilivyoelezwa hapo awali
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
     </sup>
     . Kwa ufupi, 1 × 10 zilizotolewa (IL-2 + IL-15) non-transduced (NT)-NK au CD33-directed CAR (CAR33)-NK cells zilitolewa (4D-Nucleofector; Lonza) baada ya wiki moja baada ya kutolewa au utamaduni wa ziada kwa kutumia kiasi cha Cas9:gRNA kulingana na protokoli ya awali ya kutolewa kwa NK cells
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
     </sup>
     . Cells zilikuzwa na 1 × 10 cells/ml katika 500 µL medium ya utamaduni. CAR33-
     <italic>
      KLRC1
     </italic>
     -NK cells na control cells zilikuzwa kwa angalau siku 10 baada ya kutolewa kabla ya kushiriki katika majaribio ya utendaji kwa vitro au vivo
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec18">
    <title>
     Uainishaji wa Seli za NK zilizoandaliwa
    </title>
    <p id="Par36">
     Uchanganuzi wa jeni ya
     <italic>
      KLRC1
     </italic>
     -edited NK cells ulifanywa kwa kutumia T7 endonuclease I (T7E1, NEB) na kwa uchanganuzi wa Inference of CRISPR Edits (ICE) (Synthego Performance Analysis, ICE Analysis. 2019. V3.0). PCR amplicon ya 421 bp inayojumuisha tovuti la lengo iliyotengenezwa kwa kutumia jozi ya primer (5′-ctccacctcacccttttaattg-3′ na 5′-caacttggaattctgatctttgc-3′), iliyosafishwa na kushughulikiwa na T7E1 kama ilivyoelezwa hapo awali, ambayo ilibaki 228 bp na 193 bp bands zilizokatwa, mtawalia na/au kupelekwa kwa uchanganuzi wa Sanger ili kutathmini usambazaji wa indels karibu na tovuti iliyokatwa kwa uchanganuzi wa ICE. Data yetu haikuonyesha mfuatano wa aina ya asili uliobaki katika sampuli zilizohaririwa ikilinganishwa na zisizohaririwa. Hata hivyo, kuonyesha ufanisi wa uhariri wa 100% haikuwezekana kulingana na mwongozo wa uchanganuzi wa ICE. Hasa, uchanganuzi wa ICE unategemea sana ubora wa matokeo ya uchanganuzi wa Sanger, kwa hivyo jumla ya michango yote ya indel ni sawa na thamani ya R2 na mfuatano uliobaki uliobainishwa kama sehemu isiyo na maana. Tathmini ya kina ya aleli zilizoharibiwa ilifanywa kwa uchanganuzi wa kizazi cha kwanza cha NGS kwa kutumia jozi ya primer inayojumuisha tovuti la
     <italic>
      KLRC1
     </italic>
     (5′-acctgaatctgcccccaaac-3′ na 5′-ccaagctgcacatcctagac-3′)
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      <xref ref-type="bibr" rid="CR58">
       58
      </xref>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
     </sup>
     . Maandishi ya mwisho yaliyopangwa yalichambuliwa kwa kutumia toleo la barua pepe la CRISPResso2.
    </p>
   </sec>
   <sec id="Sec19">
    <title>
     Uchambuzi wa Flow Cytometry
    </title>
    <p id="Par37">
     Usemi wa CD33-CAR na NKG2A kwenye NK cells zilizobadilishwa kwa jeni pamoja na uchafuzi unaowezekana wa cells zinazoonyesha CD3 zilichambuliwa kila baada ya siku 3-7 baada ya kutolewa kwa kutumia flow cytometry kwa kutumia mkakati wa utambulisho kama ilivyotolewa katika Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1a
     </xref>
     <sup/>
     . Usemi wa CD33-CAR ulichambuliwa kwa kuongeza CD33 protein iliyounganishwa na biotin na kuongeza pili ya anti-biotin-PE antibody (clone REA746; Miltenyi Biotec). Usemi wa NKG2A wa uso wa seli ulichambuliwa kwa kutumia anti-NKG2A-PE antibody (Clone Z199; Beckman Coulter). Ili kugundua uchafuzi wa cells zinazoonyesha CD3, anti-CD3-BUV395 antibody (clone SK7, BD Biosciences) ilikutumika. Usemi wa CD94 wa uso wa seli ulichambuliwa kwa kutumia anti-CD94-FITC antibody (Clone REA113, Miltenyi Biotec). Protokoli ya utambulisho iliyotolewa hapo awali (kwa mkakati wa utambulisho tazama Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4e
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
     </sup>
     . Tazama orodha kamili ya antibodies zote katika Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      2
     </xref>
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec20">
    <title>
     Jaribio la Kazi la Seli za CAR-NK
    </title>
    <p id="Par38">
     Uharibifu wa mwisho wa saa 4 au 24 za utamaduni wa pamoja ulioletwa na seli zisizo na utendakazi (NT)-,
     <italic>
      KLRC1
     </italic>
     -, CAR33- au CAR33-
     <italic>
      KLRC1
     </italic>
     -NK seli zilivyopimwa kwa kutumia flow cytometry. Kwa hiyo, seli zilizo na lengo zilizo na GFP au zilizoandikwa na Cell Trace CFSE proliferation kit (Invitrogen) zilifanyiwa utamaduni wa pamoja na seli za kufanya kazi kwa uwiano tofauti wa kufanya kazi-kufanya lengo (E:T) kwa muda ulioonyeshwa kwa 37 °C na 5% CO
     <sub>
      2
     </sub>
     <sup/>
     . Baada ya hapo, seli zilifungwa na 4’,6-Diamidino-2-phenylindole (DAPI) (AppliChem) na uhai wa seli za lengo ulipimwa kwa kutumia BD FACSCelesta (BD Biosciences). Ili kuchambua uharibifu wa seli katika wakati halisi, mfumo wa upigaji picha wa seli hai IncuCyte S3 (Sartorius) ulitumika kwa mujibu wa Incucyte Annexin V Dye Product Guide. Saa 96 ya sahani ya chini iliyopigwa na fibronectin (Sigma-Aldrich) iliyotolewa kwa 0.1% BSA. Ili kuona kifo cha seli katika video, IncuCyte Annexin V Red Dye (Sartorius) iliongezwa kwenye maji yanayotumika na 1 mM CaCl
     <sub>
      2
     </sub>
     kwa kiwango cha mwisho cha 2.5 µM. Seli za GFP OCI-AML2 zilifanyiwa utamaduni wa pamoja na seli za kufanya kazi kwa uwiano wa E:T wa 0.5:1, 1:1 au 2.5:1. Picha zilichukuliwa kila baada ya dakika 30 kwa kiwango cha 10x
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec21">
    <title>
     Chombo cha Cytometric Bead
    </title>
    <p id="Par39">
     Kutolewa kwa cytokine ya seli zisizo na utendakazi (NT)-,
     <italic>
      KLRC1
     </italic>
     -, CAR33- au CAR33-
     <italic>
      KLRC1
     </italic>
     -NK seli zilizo na utamaduni wa pamoja na seli za AML za mstari au seli za AML za msingi, pamoja na viwango vya cytokine katika damu ya paka tofauti za NK zilizotibiwa NSG-SGM3 zilipimwa kwa kutumia BD Cytometric Bead Array (CBA; BD Biosciences) kama ilivyoelezwa awali
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec22">
    <title>
     Utayarishaji wa Seli kwa qPCR na Uchambuzi wa Western Blot
    </title>
    <p id="Par40">
     Seli zisizo na utendakazi (NT)-,
     <italic>
      KLRC1
     </italic>
     -, CAR33- au CAR33-
     <italic>
      KLRC1
     </italic>
     -NK seli zilifanyiwa utamaduni wa pamoja na seli za OCI-AML2 kwa uwiano wa E:T wa 3:1 kwa saa 2 katika NK-MACS iliyotolewa na 5% plasma ya binadamu, 1% NK-MACS Supplements, 1% Pen/Strep na 500 U/ml IL-2 (Miltenyi Biotec au Novartis). Kisha, seli zilifungwa na 7-AAD (BD Biosciences) na kupangwa kwa kutumia kifaa cha BD FACSAria Fusion (BD Biosciences). Seli za NK zilipangwa kwa GFP/7-AAD na seli za OCI-AML2 kwa GFP/7-AAD
     <sup/>
     . Hatimaye, seli zilichangiwa, na tumba zilizohifadhiwa kwa -80 °C kwa ajili ya qPCR au uchanganuzi wa western blot. Kama udhibiti, seli za OCI-AML2 zilifanyiwa utamaduni peke yao na kutoka kwa kila aina ya seli, seli zilichangiwa na tumba zilizohifadhiwa kwa -80 °C bila utamaduni wa pamoja.
    </p>
   </sec>
   <sec id="Sec23">
    <title>
     Kuhesabu kwa mRNA ya Uwiano
    </title>
    <p id="Par41">
     RNA ilitolewa kwa kutumia peqGOLD MicroSpin total RNA kit kwa mujibu wa maagizo ya mtengenezaji (PEQLAB Biotechnologie GmbH). Utolejaji wa RNA ulijumuisha hatua ya uchanganuzi wa DNaseI kwenye safu (PEQLAB Biotechnologie GmbH). Uundaji wa cDNA ulifanywa kwa kutumia RevertAid first strand cDNA synthesis kit (ThermoFisher), kwa kutumia kiasi sawa cha 1 µg ya RNA kwa kila sampuli. qRT-PCR ilifanywa kwa kutumia QuantStudio Flex 7 qRT-PCR cycler (Applied Biosystems) kwa kutumia Sybr Green PCR master mix (Applied Biosystmes). Kwa ajili ya primers zinazotumika tazama Jedwali la Ziada la
     <xref ref-type="supplementary-material" rid="MOESM1">
      3
     </xref>
     <sup/>
     . Uwiano wa RNA ulihesabiwa kwa kutumia njia ya ΔΔCq kama ilivyoelezwa hapo awali
     <sup>
      <xref ref-type="bibr" rid="CR59">
       59
      </xref>
      ,
      <xref ref-type="bibr" rid="CR60">
       60
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec24">
    <title>
     Western Blot
    </title>
    <p id="Par42">
     Uchunguzi wa kiwango cha usemi wa protini ulifanywa katika tumba za seli zote, zilizochanjwa katika Triton-X buffer (30 mM Tris pH [7.4], 150 mM NaCl, 1% Triton-X, 10% glycerol, 0.5 mM PMSF, 2 mM DTT, 1x protease inhibitor cocktail (Roche)). Vifaa vifuatavyo vya uchunguzi wa Western blot vilikuwa vinatumika: rabbit anti-Caspase-3 (Cell Signaling, 9662S), mouse anti-Caspase-8 (Enzo, ADI-AAM-118-E), mouse anti-PARP (poly(ADD)ribose polymerase) (Cell Signaling, 9546S), mouse anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase) (BioTrend, 5G4-6C5), rabbit anti-Caspase-9 (Cell Signaling, 9502S), goat anti-mouse (Abcam, ab6789), goat anti-rabbit (Abcam, ab6721). Vifaa vya pili vilivyochanganywa na horseradish peroxidase, na ishara ilipatikana kwa kutumia substrate ya uchunguzi wa chemiluminescence (ThermoFisher). Tazama orodha kamili ya vifaa vyote vya uchunguzi katika Jedwali la Ziada la
     <xref ref-type="supplementary-material" rid="MOESM1">
      2
     </xref>
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec25">
    <title>
     Utayarishaji wa Seli kwa Uchambuzi wa CITE-Seq
    </title>
    <p id="Par43">
     Kwa uchambuzi wa kuainisha seli moja moja, seli za NK zilizohifadhiwa (zimebadilishwa kijeni) kutoka kwa wadonaji tofauti watatu zilitolewa na kuzalishwa kwa kiwango cha 2 × 10 seli/ml katika sahani ya 48-nafasi katika 750 µl ya maji ya NK-MACS yenye 1% ya viungio vya NK-MACS, 5% ya plasma ya binadamu, 1% ya Pen/Strep, 500 U/ml IL-2 (Miltenyi Biotec au Novartis) pamoja na 50 ng/ml IL-15 (CellGenix) kwa kila nafasi. Siku tatu baadaye seli zilichukuliwa na kuzamishwa na seli za OCI-AML2 katika sahani za 6 cm kwa uwiano wa E:T wa 1:1. Seli za OCI-AML2 zilikuwa zimechangiwa mapema na Kit wa Cell Trace CFSE wa ukuaji (Invitrogen) kulingana na utaratibu wa mfumo. Kama udhibiti, seli za NK zilikuwa zimezalishwa bila kuwasiliana na seli za AML. Baada ya masaa 2 seli zilizowekwa zilichukuliwa, na Fc-block ilifanywa kwa kutumia antibodies za hIgG (Kiovig na Intratect, Hospitali ya Chuo Kikuu cha Frankfurt). Kisha, seli zilichangiwa na antibodi ya anti-NKG2A-PE (Clone Z199, Beckman Coulter), kiambatisho cha CD33-CAR-uchunguzi (CD33-protein-biotin + anti-biotin-APC (Clone RE746, Miltenyi Biotec) kulingana na aina ya seli na kila hali iliyopewa lebo tofauti ya SampleTag kutoka kwa Kit ya Kuainisha Seli za Binadamu za Kibinafsi za BD Biosciences. Kisha, seli zilichangiwa na 7-AAD (BD Biosciences) ili kuepuka seli zilizokufa na kuchambuliwa kwa kutumia mashine ya BD FACSAria. Seli za NK zilichambuliwa kama ifuatavyo: NT-NK kama CFSE,
     <italic>
      KLRC1
     </italic>
     -NK kama CFSE/NKG2A, CAR33-NK kama CFSE/CAR na seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK kama CFSE/NKG2A/CAR. Kisha, uchanganuzi wa seli moja moja ulifanywa kwa kutumia mfumo wa uchanganuzi wa Seli Moja wa BD Rhapsody (BD Biosciences)
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec26">
    <title>
     Uchambuzi wa CITE-Seq wa Seli moja moja ya Transkriptoma na Epitopu kwa Kutumia Mbinu ya Kuandika (CITE-Seq)
    </title>
    <p id="Par44">
     Kwa uchambuzi wa seli moja moja wa maandishi na epitopi, seli zilizochaguliwa zilijumuishwa katika tufe ya 5 ml ya FACS, ili kuchambua idadi sawa ya seli kutoka kwa kila mdonaji na kila hali. Seli zilifungwa mara moja na kisha kusukumwa tena katika 100 µL ya Stain Buffer (BSA) (BD Biosciences, cat# 554657). Kisha, seli zilichanganywa na mchanganyiko wa kufa kwa kila moja ya antibodies 49 za BD AbSeq zilizoambatishwa na oligonucleotide (BD Biosciences; tazama Jedwali la Ziada la
     <xref ref-type="supplementary-material" rid="MOESM1">
      4
     </xref>
     ) kwa dakika 40 kwenye barafu. Baada ya kufungwa mara mbili kwa BD Stain Buffer, seli zilijaza tena katika 620 µL ya bufu ya sampuli ya BD (BD Biosciences, kit ya kujaza kwa cartridge, cat# 633731). Mchanganyiko wa seli ulichangiwa na 3.1 µL 2 mM Calcein AM (BD Biosciences, cat# 564061) na 3.1 µL Draq7 (BD Biosciences, cat# 564904) kwa dakika 5 kwa 37 °C katika giza. Mwani wa seli na uhai ulipimwa kwa kutumia 10 µL ya mchanganyiko wa seli uliochangiwa katika hemocytometer ya kuchanganya (Incyto, cat# DHC-N01-5) na skanner ya BD Rhapsody. Mchanganyiko wa seli wenye seli 40,000 zilizokamatwa ulijipanga na kuwekwa mara moja kwenye kartridge ya BD Rhapsody (BD Biosciences, cat# 633733) kulingana na utaratibu wa mfumo. Mabua ya kuambatisha oligonucleotide yaliwekwa kwenye kartridge na seli zilichakata kwa kutumia bufu ya kuchakata yenye 5 mM DTT. Mabua yaliyokamata maandishi ya mRNA, lebo za sampuli na antibodies zilizoambatishwa na oligonucleotide zilijumuishwa kabla ya kufanywa kinyume na utendakazi wa exonuclease I (BD Biosciences, kit ya cDNA, cat# 633773). Maktaba ya DNA yalijipanga kwa kutumia kit ya uimarishaji wa mRNA na AbSeq ya BD Rhapsody (BD Biosciences, cat# 633774). Kwa hiyo, paneli iliyopangwa mapema ya Jibu la Kinga ya Binadamu (BD Biosciences, cat# 633750) ilikutumika pamoja na paneli ya kuambatisha kwa majeni 434 tofauti (tazama Jedwali la Ziada la
     <xref ref-type="supplementary-material" rid="MOESM1">
      5
     </xref>
     ) kulingana na utaratibu wa mfumo. Uwiano na saizi ya maktaba ya mwisho yenye viambajengo kwa ajili ya uwekaji alama wa Illumina ulipimwa kwa kutumia Qubit 4 Fluorometer yenye kit ya dsDNA ya High Sensitivity (ThermoFisher Scientific, cat# Q32851) na Agilent 4150 Tapestation yenye High Sensitivity D1000 screentape (Agilent, cat# 5067-5584, 5067-5585). Maktaba hayo yalijumuishwa hadi uwiano wa mwisho wa 1 nM na kuchambuliwa pamoja na 20% ya DNA ya PhiX katika mizunguko mingi (75 bp jozi) kwenye kichambuzi cha NextSeq2000 (Illumina).
    </p>
   </sec>
   <sec id="Sec27">
    <title>
     Uchambuzi wa Data ya CITE-Seq
    </title>
    <p id="Par45">
     Faili za FASTQ zilizopatikana ziliwekwa pamoja na mfuatano wa marejeleo ya maandishi ya mRNA na AbSeq kwenye jukwaa la SevenBridges (Seven Bridges Genomics,
     <ext-link ext-link-type="uri" href="https://www.sevenbridges.com">
      https://www.sevenbridges.com
     </ext-link>
     ) na kuchakata kwa kutumia mfumo wa uchanganuzi wa BD Rhapsody (BD Biosciences) kwa viwango vya kawaida. Kwa hiyo, jozi za kusoma za ubora duni zilitolewa na kusomwa zilizobaki za R1 zilijumuishwa na lebo za seli na kipeo cha kipekee cha utambulisho (UMI)s. Soma za R2 zilijumuishwa kwenye mfuatano wa marejeleo wa maandishi na kusoma na lebo za seli sawa, mfuatano wa UMI na jina la marejeleo lililofanywa kuwa molekuli moja. Baada ya hapo, algorithm ya kurekebisha makosa ya kubadilisha kwa kujirudia (RSEC) ilikutumika kurekebisha hesabu za molekuli kwa makosa ya uwekaji alama. Hatimaye, hesabu za seli zilifikiriwa, na lebo za sampuli zilijumuishwa na seli ili kujenga matrixi za hesabu za molekuli zilizorekebishwa na RSEC.
    </p>
   </sec>
   <sec id="Sec28">
    <title>
     Muundo wa Data ya Ingizo
    </title>
    <p id="Par46">
     Matrixi za hesabu za molekuli zilizorekebishwa na RSEC za wadonaji D1 na D2 ziligawanywa katika matrixi mbili za seli kwa kila kipengee, moja kwa usemi wa jeni (RNA) na nyingine kwa usemi wa alama za uso (lebo za kuzalishwa na kinga, ADT). Jumla ya seli 60,957 zilitumika kwa uchanganuzi (tazama Jedwali la Ziada la
     <xref ref-type="supplementary-material" rid="MOESM1">
      6
     </xref>
     kwa muhtasari wa utuputupu wa jukwaa la Seven Bridges Genomics).
    </p>
   </sec>
   <sec id="Sec29">
    <title>
     Mfumo wa Utayarishaji
    </title>
    <p id="Par47">
     Tulichakata data kwa kuchunguza vipimo vya udhibiti wa ubora (QC) na kufuta seli kulingana na vigezo vilivyofafanuliwa na mtumiaji, kwa kufuata mapendekezo ya Tomislav Ilicic et al. (2016)
     <sup>
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
     </sup>
     . Tuliondoa seli zilizopewa lebo kama
     <italic>
      multiplets
     </italic>
     au
     <italic>
      undetermined
     </italic>
     na jukwaa la Seven Bridges Genomics. Zaidi ya hayo, tulitumia
     <italic>
      scater
     </italic>
     kuondoa waliotengwa kulingana na saizi ya maktaba na idadi ya vipengele vilivyogunduliwa. Baada ya uchakataji, seli 32,908 na 20,197 kutoka D1 na D2 zilihifadhiwa. Hatimaye, hesabu za RNA zilirekebishwa na kubadilishwa kwa logariti kwa kutumia
     <italic>
      logNormCounts
     </italic>
     na hesabu za ADT zilirekebishwa kwa kutumia njia ya uwiano wa kituo (CLR), iliyokokotolewa kwa kila kipengee
     <sup>
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ,
      <xref ref-type="bibr" rid="CR62">
       62
      </xref>
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ,
      <xref ref-type="bibr" rid="CR63">
       63
      </xref>
      <xref ref-type="bibr" rid="CR63">
       63
      </xref>
      ,
      <xref ref-type="bibr" rid="CR64">
       64
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec30">
    <title>
     Kusoma Athari ya CAR33 na
     <italic>
      KLRC1
     </italic>
     -KO kwenye Seli za NK kwenye Usemi wa Transkripti na Alama za Usemi kabla ya Kuwasiliana na Seli za AML
    </title>
    <sec id="Sec31">
     <title>
      Uchambuzi wa Usemi wa Jeni tofauti
     </title>
     <p id="Par48">
      Uchakataji wa data kwenye seti mbili zilizounganishwa za wadonaji D1 na D2 zilitolewa kando kwenye meza za hesabu za RNA na ADT. Tulitumia mbinu ya pseudo-bulk, ambapo tulijumlisha hesabu za kipengele kwa vikundi vya seli kulingana na hali (NT-NK,
      <italic>
       KLRC1
      </italic>
      -NK, CAR33-NK na CAR33-
      <italic>
       KLRC1
      </italic>
      -NK seli) na mdonaji (D1 na D2). Kwa uchambuzi wa usemi wa RNA na ADT, tulitumia
      <italic>
       edgeR
      </italic>
      na
      <italic>
       limma
      </italic>
      , mtawalia
      <sup>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      .
     </p>
     <p id="Par49">
      Tulibuni matrix ya muundo kulingana na vigeu tofauti vinavyofaa (kwa kutumia fomula ya muundo: ~mdonaji + CAR + KO + CAR:KO). Kwa RNA, tulipasisha muundo wa quasi-likelihood negative binomial generalized log-linear kwa data ya hesabu, na kutathmini usemi wa transkripti kwa kiwango fulani cha fold-change (=log2(1.2)) kwa kutumia
      <italic>
       glmQLFit
      </italic>
      na
      <italic>
       glmTreat
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
      </sup>
      . Kwa upande wa ADT, tulibadilisha data ya hesabu kuwa log2-hesabu kwa milioni (logCPM) kwa kutumia
      <italic>
       voom
      </italic>
      , na kupasisha muundo wa mstari kwa kila kipengele kwa kutumia
      <italic>
       lmFit
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      . Baada ya hapo, mbinu ya empirical Bayes na chaguo za
      <italic>
       treat
      </italic>
      zilitumika kutathmini usemi wa alama za uso kwa kiwango fulani cha fold-change (=log2 (1.05))
      <sup>
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
       <xref ref-type="bibr" rid="CR66">
        66
       </xref>
       ,
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
      </sup>
      . Hatimaye, kwa kuzingatia tofauti fulani, vipengele vyote vya RNA na ADT vilipangwa kwa thamani ya
      <italic>
       p
      </italic>
      - au mabadiliko ya logarithmic kamili (logFC) na kugawanywa katika vikundi vya juu au chini kwa kutumia
      <italic>
       decideTests
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      . Tuliripoti matokeo yetu katika grafu za volcano (
      <italic>
       ggplot2
      </italic>
      ) na dot plots (
      <italic>
       scater
      </italic>
      ) huku tukionyesha vipengele maalum vya maslahi
      <sup>
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
      </sup>
      .
     </p>
    </sec>
    <sec id="Sec32">
     <title>
      Uchambuzi wa Seli moja moja
     </title>
     <p id="Par50">
      Baada ya kusoma athari ya jumla ya kila moja ya hali tatu kwenye kiwango cha pseudo-bulk, pia tuliendelea na uchanganuzi wa kina zaidi kwenye seli kabla ya co-culture kwenye kiwango cha seli moja. Wadonaji wawili D1 na D2 walichambuliwa kando.
     </p>
    </sec>
    <sec id="Sec33">
     <title>
      Uchakataji wa Data na Kujumuisha
     </title>
     <p id="Par51">
      Hesabu za kipengele za ADT na RNA zilijumuishwa katika matrix moja ya kipengele. Uchambuzi wa mchanganyiko wa kipengele (PCA) ulifanywa na vipengele 20 kabla ya kufanya klabu za Louvain
      <sup>
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="CR70">
        70
       </xref>
       ,
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="CR72">
        72
       </xref>
      </sup>
      . Thamani tofauti za kigezo
      <italic>
       k
      </italic>
      , kinachoashiria idadi ya majirani, zilitathminiwa na kutathminiwa kwa kutumia alama za ufanano wa klabu (adjusted rand index (ARI) &amp; weighted rand index (WRI)). Matokeo ya klabu za Louvain na
      <italic>
       k
      </italic>
      = 50 yalitoa idadi ya klabu zinazofaa na zilipata alama ya juu zaidi katika alama zote mbili za ufanano (Supplementary Fig.
      <xref ref-type="supplementary-material" rid="MOESM1">
       S3c
      </xref>
      ) na zilitumika katika uchanganuzi wa matokeo. Matokeo yalipigwa kwenye t-distributed stochastic neighbor embedding (t-SNE)
      <sup>
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      .
     </p>
    </sec>
   </sec>
   <sec id="Sec34">
    <title>
     Kusoma Athari ya Kuwasiliana na Seli za AML kwenye Usemi wa Transkripti na Alama za Usemi baada ya Kuwasiliana na Seli za AML
    </title>
    <p id="Par52">
     Baada ya kusoma athari ya
     <italic>
      KLRC1
     </italic>
     , CAR33 na mwingiliano wao pamoja, tulitaka kuelewa mabadiliko ya usemi wa jeni na alama za uso baada ya AML-co-culture. Tuliunganisha seti zote mbili za D1 na D2 bila kuzigawanya seli kulingana na AML-co-culture. Hii iliruhusu kulinganisha seli kabla ya co-culture na zile baada ya. Kwa jumla, tulikuwa na seli 53,105, ambazo 29,607 zilikuwa zimechanganywa na seli za AML. Tulitumia mbinu ya pseudo-bulk, ambapo tulijumlisha hesabu za kipengele kwa vikundi vya seli kulingana na kabla/baada ya co-culture, hali (NT-NK,
     <italic>
      KLRC1
     </italic>
     -NK, CAR33-NK na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK seli) na mdonaji (D1 na D2)
     <sup/>
     .
    </p>
    <sec id="Sec35">
     <title>
      Uchambuzi wa Usemi wa Jeni tofauti
     </title>
     <p id="Par53">
      Tulitengeneza mfumo wetu wa matrix kwa ajili ya michanganyiko tofauti kwa kutumia fomula ya muundo: ~ coculture + CAR + KO + CAR:KO. Kutoka hapa, utaratibu uleule ulioelezwa katika sehemu ya mbinu “Kusoma athari ya CAR33 na KLRC1-KO kwenye seli NK” ulitumika. Kwa kuongezea, tulitumia
      <italic>
       scran
      </italic>
      ’s
      <italic>
       find Markers
      </italic>
      chaguo za kukusanya kwa ajili ya kusoma vipengele tofauti vilivyoonyeshwa katika kila hali baada ya co-culture. Tulihesabu thamani za logFC za vipengele vya RNA na ADT kwa kila hali baada ya co-culture wakati wa kulinganisha na hali ile ile kabla ya co-culture. Hii iliruhusu tusome athari ya co-culture kwenye hali za mtu binafsi, badala ya athari ya jumla inayoonyeshwa katika grafu za awali. Matokeo yalionyeshwa kwenye heatmap
      <sup>
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
      </sup>
      <sup/>
      .
     </p>
    </sec>
    <sec id="Sec36">
     <title>
      Uchambuzi wa Seli moja moja
     </title>
     <p id="Par54">
      Baada ya kuelewa athari ya jumla ya co-culture kwenye kiwango cha pseudo-bulk, tulitaka kusoma hiyo kwenye kiwango cha seli moja. Kwa kutofautiana na uchambuzi wetu wa pseudo-bulk, tulizingatia seli baada ya co-culture katika uchanganuzi wetu wa seli moja na tukasoma wadonaji D1 na D2 kibinafsi ili kuepuka masuala ya mabadiliko. Hii ilijumuisha seli 18,604 na 11,003 kutoka D1 na D2, mtawalia.
     </p>
    </sec>
    <sec id="Sec37">
     <title>
      Uchakataji wa Data
     </title>
     <p id="Par55">
      Vile vile na uchanganuzi wa seli moja wa awali, PCA ilihesabiwa na vipengele 20 na Louvain clustering ilifanywa kwenye maadili yaliyochanganywa ya ADT na RNA kwa kutumia
      <italic>
       scran
      </italic>
      na
      <italic>
       k
      </italic>
      = 50, na
      <italic>
       igraph
      </italic>
      <sup/>
      . Matokeo yalionyeshwa kwenye ramani ya t-SNE. Alama mbalimbali za jumla kwa ajili ya vipengele vya alama vinavyotofautisha kati ya makundi vilihesabiwa kwa kutumia
      <italic>
       scoreMarkers
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR72">
        72
       </xref>
       ,
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      . Maadili ya usemi ya vipengele vya juu kulingana na wastani wa Eneo Chini ya Mkunjo (AUC) wa kundi la maslahi yalionyeshwa kwenye grafu ya nukta kwa makundi yote.
     </p>
    </sec>
   </sec>
   <sec id="Sec38">
    <title>
     Uchunguzi wa Kazi wa Seli za CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK kwenye Mice waliozalishwa kwa njia za kigeni
    </title>
    <p id="Par56">
     NOD.Cg-
     <italic>
      Prkdc
     </italic>
     <italic>
      Il2rg
     </italic>
     Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ (NSG-SGM3) panya zilitolewa kutoka
     <italic>
      The Jackson Laboratory
     </italic>
     , Bar Harbor, ME, USA (JAX stock No.: #013062 (NSG-SGM3)
     <sup>
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
     </sup>
     . Panya hizi zililiwa chini ya hali maalum za kuzuia vimelea na kuwa na ufikiaji wa chakula na maji, na panya za majaribio na za udhibiti zilikuwa zikila pamoja. Kwa ajili ya muundo wa panya wa xenograft wa OCI-AML2, seli 0.5×10 za OCI-AML2 (GFP, Luc) zilitolewa kwenye shira za panya NSG-SGM3 (≤wiki 15, wanaume). Siku mbili/tatu baada ya kutumia seli za AML, uwekaji wa seli za leukemic ilipimwa kwa kutumia luciferin chini ya ngozi na kuchambua ishara ya bioluminescence kwa kutumia mfumo wa upigaji picha wa IVIS Lumina II Multispectral (PerkinElmer). Siku tatu/saba na kumi 5 × 10 au 3 × 10 seli za NK zisizo na utoaji (NT),
     <italic>
      KLRC1
     </italic>
     , CAR33, au CAR33-
     <italic>
      KLRC1
     </italic>
     zilitolewa kwenye shira za panya, wakati kundi moja la panya halikuwa na matibabu. Seli za NK zilitolewa kutoka kwa mdonaji mmoja na zilikuwa zimekuzwa kwa siku 18 baada ya utoaji wa nyuklia wakati wa uwekaji wa kwanza na siku 25 baada ya utoaji wa nyuklia wakati wa uwekaji wa pili. Kwa kuongezea, siku ya uwekaji wa seli za NK, uwekaji wa kila siku wa chini ya ngozi wa 25,000 IU IL-2 (Novartis) ulianzishwa kwa ajili ya panya waliopokea seli za NK. Kuonekana, tabia, na uzito wa wanyama walipimwa kila siku 2-3 na uzito wa leukemic ulipimwa kwa kutumia BLI, na euthanasia ilifanywa kwa kutumia kuvunja shingo chini ya anestesia ya isoflurane. Siku 17 panya walichinjwa au walipelekwa kwenye majaribio ya maisha. Kwa ajili ya uchanganuzi wa uwekaji wa tenzi ya BM, seli za BM zilitolewa kutoka kwa kila panya na zililiwa katika RPMI1640 na Glutamax, +10% FCS, +1% P/S hadi uwekaji wa ndani. Seli za BM kutoka kwa kila kundi la matibabu zilichanganywa na 5 × 10 seli zilitolewa kwenye shira za panya NSG-SGM3 (≤wiki 16, wanaume/wanawake). Panya walipimwa kwa uzito na walipimwa kila wiki na uchanganuzi wa BLI ulifanywa ili kugundua ukuaji wa seli za leukemic. Panya walichinjwa wakati thamani za BLI zilikuwa zimezidi (muda wa kuchukua picha wa ~60,000 counts), au vigezo vya kuzalia vilipofikiwa (hasara ya uzito ya zaidi ya 20% ya uzito wa kawaida, dalili kama vile: kutokujali, athari za kulinda zinazotambulika, ngozi iliyopungua, matatizo ya kupumua, kuhara, matatizo ya mwili (kama vile kukunja, harakati za kujitegemea), au nafasi isiyo ya kawaida, isiyo ya asili ya mwili (kama vile nafasi ya kujikunja, opisthotonus). Majaribio yote hayo yalidhibitiwa na Regierungspräsidium Darmstadt, Ujerumani
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec39">
    <title>
     Uchambuzi wa Takwimu
    </title>
    <p id="Par57">
     Kwa ajili ya uchanganuzi wa takwimu, usambazaji wa kawaida wa utendakazi wa seli za NK ulidhaniwa kutokana na matumizi ya wadonaji wenye afya kama chanzo cha seli za NK. Kuhusiana na majaribio ya panya ya maisha, usambazaji wa kawaida pia unaweza kudhaniwa. Uchanganuzi wa takwimu ulifanywa kwa kutumia GraphPad PRISM toleo 6–9 (GraphPad Software, Inc.) kwa majaribio na wadonaji zaidi ya watatu/wawili.
    </p>
   </sec>
   <sec id="Sec40">
    <title>
     Ripoti ya Mafunzo
    </title>
    <p id="Par58">
     Maelezo zaidi kuhusu muundo wa utafiti yanapatikana katika
     <xref ref-type="supplementary-material" rid="MOESM9">
      Nature Portfolio Reporting Summary
     </xref>
     iliyoambatanishwa na makala haya.
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Shukrani
   </title>
   <p>
    Watu walioandika wanashukuru wagonjwa wote waliotoa michango katika utafiti huu kwa kutoa sampuli za leukapheresis. Watu walioandika wanashukuru Ralf Schubert kwa usaidizi na uchambuzi wa CBA, na Petra Dinse, Petra Schoen, Bernd Lecher, Simone Maurer, Beate vom Hövel, Daniela Brücher, Katja Stein, Franziska Ganß kwa usaidizi wao bora wa kiufundi, Lea Knapp kwa usaidizi wa majaribio, Sarah Mertlitz kwa usaidizi wa kuunda picha za confocal microscopy, na wafanyakazi wa kituo cha wanyama cha GSH na jukwaa la FCI immunmonitoring kwa usaidizi wa majaribio, na Christian Brandts kwa usaidizi na Hifadhi ya UCT inayotoa sampuli za AML. Tunashukuru Lisa Marie Reindl kwa majadiliano yenye manufaa. Zaidi ya hayo, tunashukuru washirika wa ushirikiano wa viwanda kutoka BD Bioscience, Sartorius, PerkinElmer, Revvity na Miltenyi Biotec kwa usaidizi bora wa matumizi ya kiufundi. Kazi hii ilisaidiwa na Stiftung Deutsche Krebshilfe (Misaada ya Ujerumani ya Kansa) katika miradi mahususi (#70114124 kwa E.U., M.V.) ndani ya Mpango wa Utafiti wa Uhamasishaji wa Saratani (#70114180 kwa N.A., E.U.) na wa "CAR FACTORY" (#70115200 kwa E.U., T. Ca.), na Deutsche Forschungsgemeinschaft (DFG, Shirika la Utafiti la Ujerumani) ndani ya SFB/IRTG 1292 (Mradi wa #318346496 kwa E.U., N.A., L.B.) na miradi mahususi RI 2462/9-1 na RI 2462/10-1 (kwa M.A.R), na CA 311/7-1 (kwa T.Ca.), na Jose Carreras Leukemia Foundation (kwa E.U., O.P., M.A.R. kwa DJCLS 11R/2020, 23R/2021 na DJCLS 15R/2023), na Deutsche Kinderkrebsstiftung DKS_2023_01 (kwa M.V.), na shirika la "Hilfe für krebskranke Kinder Frankfurt e.V." ndani ya kongamano la C
    <sup>
     3
    </sup>
    OMBAT-AML (kwa J.-H.K., R.B., E.U.); na Kituo cha Utafiti wa Saratani cha Frankfurt (FCI, Wizara ya Elimu ya Juu, Utafiti na Sanaa ya Jimbo la Hessen, III L 5 − 519/03/03.001). T.B. alisaidiwa na DFG, INDEEP Clinician Scientist Program (Mradi wa #493624332), T.B., K.I., S.W. na A.A. walisisaidiwa na MSNZ Frankfurt (Misaada ya Ujerumani ya Kansa), na H.M.R. na Wizara ya Elimu ya Juu ya Misri kwa ufadhili wa ufadhili wa baada ya udaktari wa miezi sita katika kikundi cha utafiti cha O.P., Charite University Berlin, Ujerumani. Fig. zimeundwa kwa kutumia BioRender CC-BY leseni (Fig.
    <xref ref-type="fig" rid="Fig1">
     1
    </xref>
    a, Fig.
    <xref ref-type="fig" rid="Fig2">
     2
    </xref>
    a, Fig.
    <xref ref-type="fig" rid="Fig5">
     5
    </xref>
    a
    <xref ref-type="fig" rid="Fig6">
     6a
    </xref>
    , sehemu ya Fig.
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    a, Fig.
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    e, Fig.
    <xref ref-type="fig" rid="Fig7">
     7h
    </xref>
    , na Fig. ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM1">
     2a
    </xref>
    ).
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Michango ya Waandishi
   </title>
   <p>
    T.B., N.A., L.B., P.W., A.G., V.S., J.A. H.M.R., B.A.J. walifanya majaribio; A.G. alifanya utayarishaji na A.A., K.I. walichambua data ya CITE-seq. V.S., M.V. walichambua data ya qPCR. S.W. alitoa data ya kimatibabu. N.A., T.B., L.B. walichambua data zote zingine. E.U., K.I., N.A., T.B. waliunda na kuongoza utafiti; N.A., T.B., A.A., K.I. walifanya uchambuzi wa takwimu; E.U., K.I., R.B., T.O., J.-H.K., O.P., M.A.R., T.Ca.; N.M., M.V. walijadili matokeo pamoja na waandishi wote. T.B., N.A., K.I., E.U. waliandika makala hii kwa ushirikiano na waandishi wote.
   </p>
  </sec>
  <sec sec-type="peer-review">
   <title>
    Uchunguzi wa Wataalamu
   </title>
   <sec id="FPar1">
    <title>
     Maelezo ya Uchunguzi wa Wataalamu
    </title>
    <p id="Par59">
     <italic>
      Nature Communications
     </italic>
     thanks May Daher, Naval Daver, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
    </p>
   </sec>
  </sec>
  <sec>
   <title>
    Ufadhili
   </title>
   <p>
    Open Access funding enabled and organized by Projekt DEAL.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa Data
   </title>
   <p>
    All sequencing data concerning CITE-seq experiments has been deposited in the NCBI GEO repository under accession number
    <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE221552">
     GSE221552
    </ext-link>
    .
    <xref ref-type="sec" rid="Sec42">
     Source data
    </xref>
    are provided with this paper.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa Kifaa cha Kompyuta
   </title>
   <p>
    All code used to analyze CITE-seq data is available in the following github repository:
    <ext-link ext-link-type="uri" xlink:href="https://github.com/AGImkeller/CD33_NK_cells_2022">
     https://github.com/AGImkeller/CD33_NK_cells_2022
    </ext-link>
    .
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar2" sec-type="COI-statement">
    <title>
     Mashindano ya Kimaslahi
    </title>
    <p id="Par60">
     E.U. has a sponsored research project with Gilead and BMS and acts as medical advisor of Phialogics and CRIION. T.O. has disclosures to Merck KGaA: Honoraria; Gilead: Research Funding; Merck KGaA: Research Funding; Roche: Honoraria. O.P. has received honoraria or travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, Novartis, Pfizer, and Therakos, he has received research support from Gilead, Incyte, Jazz, Neovii Biotech, and Takeda and is member of advisory boards to Jazz, Gilead, MSD, Omeros, Priothera, Shionogi, and SOBI. N.M. is employee of Miltenyi Biotec. T.B., P.W., E.U. have filed patents on data partly published in this manuscript: PCT/EP2024/060767: Treatment of leukemia with engineered immune checkpoint inactivated CAR-NK cells and CAR-T cells (U31175WO). No competing interests exists for the remaining authors.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    Marudio
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Albinger
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <name>
        <surname>
         Hartmann
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Ullrich
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
      </article-title>
      <source>
       Gene Ther.
      </source>
      <year>
       2021
      </year>
      <volume>
       28
      </volume>
      <fpage>
       513
      </fpage>
      <lpage>
       527
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXntVOrsL8%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33753909
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8455322
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41434-021-00246-w
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Maude
        </surname>
        <given-names>
         SL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2018
      </year>
      <volume>
       378
      </volume>
      <fpage>
       439
      </fpage>
      <lpage>
       448
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXitlylsLw%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       29385370
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5996391
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1709866
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Munshi
        </surname>
        <given-names>
         NC
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Idecabtagene vicleucel in relapsed and refractory multiple myeloma
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2021
      </year>
      <volume>
       384
      </volume>
      <fpage>
       705
      </fpage>
      <lpage>
       716
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXlt1KgsLY%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33626253
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa2024850
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bouchkouj
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       FDA approval summary: brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
      </article-title>
      <source>
       Oncologist
      </source>
      <year>
       2022
      </year>
      <volume>
       27
      </volume>
      <fpage>
       892
      </fpage>
      <lpage>
       899
      </lpage>
      <pub-id pub-id-type="pmid">
       35983953
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9526496
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/oncolo/oyac163
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Maude
        </surname>
        <given-names>
         SL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Chimeric antigen receptor T cells for sustained remissions in leukemia
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2014
      </year>
      <volume>
       371
      </volume>
      <fpage>
       1507
      </fpage>
      <lpage>
       1517
      </lpage>
      <pub-id pub-id-type="pmid">
       25317870
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4267531
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1407222
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Liu
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2020
      </year>
      <volume>
       382
      </volume>
      <fpage>
       545
      </fpage>
      <lpage>
       553
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXjtlCgtro%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       32023374
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7101242
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1910607
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Marin
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2024
      </year>
      <volume>
       30
      </volume>
      <fpage>
       772
      </fpage>
      <lpage>
       784
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXhvFantrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       38238616
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10957466
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41591-023-02785-8
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Döhner
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <name>
        <surname>
         Weisdorf
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Bloomfield
        </surname>
        <given-names>
         CD
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Acute myeloid leukemia
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2015
      </year>
      <volume>
       373
      </volume>
      <fpage>
       1136
      </fpage>
      <lpage>
       1152
      </lpage>
      <pub-id pub-id-type="pmid">
       26376137
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMra1406184
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Haubner
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
      </article-title>
      <source>
       Leukemia
      </source>
      <year>
       2019
      </year>
      <volume>
       33
      </volume>
      <fpage>
       64
      </fpage>
      <lpage>
       74
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BB3c%2FitFGqsA%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       29946192
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41375-018-0180-3
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ehninger
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
      </article-title>
      <source>
       Blood Cancer J.
      </source>
      <year>
       2014
      </year>
      <volume>
       4
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC2cfis1yktA%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       24927407
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4080210
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/bcj.2014.39
      </pub-id>
      <elocation-id>
       e218
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Dutour
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia
      </article-title>
      <source>
       Adv. Hematol.
      </source>
      <year>
       2012
      </year>
      <volume>
       2012
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC387nt1WhtA%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       22272203
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3261457
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1155/2012/683065
      </pub-id>
      <elocation-id>
       683065
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kim
        </surname>
        <given-names>
         MY
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia
      </article-title>
      <source>
       Cell
      </source>
      <year>
       2018
      </year>
      <volume>
       173
      </volume>
      <fpage>
       1439
      </fpage>
      <lpage>
       1453.e19
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXhtVKntrfP
      </pub-id>
      <pub-id pub-id-type="pmid">
       29856956
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6003425
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cell.2018.05.013
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Reindl
        </surname>
        <given-names>
         LM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Immunotherapy with NK cells: recent developments in gene modification open up new avenues
      </article-title>
      <source>
       Oncoimmunology
      </source>
      <year>
       2020
      </year>
      <volume>
       9
      </volume>
      <pub-id pub-id-type="pmid">
       33457093
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7781759
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1080/2162402X.2020.1777651
      </pub-id>
      <elocation-id>
       1777651
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Szczepanski
        </surname>
        <given-names>
         MJ
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors
      </article-title>
      <source>
       Cancer Immunol. Immunother.
      </source>
      <year>
       2010
      </year>
      <volume>
       59
      </volume>
      <fpage>
       73
      </fpage>
      <lpage>
       79
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXht1OnsL%2FO
      </pub-id>
      <pub-id pub-id-type="pmid">
       19526239
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s00262-009-0724-5
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rubnitz
        </surname>
        <given-names>
         JE
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia
      </article-title>
      <source>
       J. Clin. Oncol.
      </source>
      <year>
       2010
      </year>
      <volume>
       28
      </volume>
      <fpage>
       955
      </fpage>
      <lpage>
       959
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC3cXktF2ltrw%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       20085940
      </pub-id>
      <pub-id pub-id-type="pmcid">
       2834435
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1200/JCO.2009.24.4590
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Romee
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
      </article-title>
      <source>
       Sci. Transl. Med.
      </source>
      <year>
       2016
      </year>
      <volume>
       8
      </volume>
      <fpage>
       357ra123
      </fpage>
      <pub-id pub-id-type="pmid">
       27655849
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5436500
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1126/scitranslmed.aaf2341
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Miller
        </surname>
        <given-names>
         JS
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2005
      </year>
      <volume>
       105
      </volume>
      <fpage>
       3051
      </fpage>
      <lpage>
       3057
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2MXjtlSmtb0%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       15632206
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood-2004-07-2974
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Paczulla
        </surname>
        <given-names>
         AM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
      </article-title>
      <source>
       Nature
      </source>
      <year>
       2019
      </year>
      <volume>
       572
      </volume>
      <fpage>
       254
      </fpage>
      <lpage>
       259
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXhtl2qsLvF
      </pub-id>
      <pub-id pub-id-type="pmid">
       31316209
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6934414
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41586-019-1410-1
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR19">
     <label>
      19.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Albinger
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
      </article-title>
      <source>
       Blood Cancer J.
      </source>
      <year>
       2022
      </year>
      <volume>
       12
      </volume>
      <pub-id pub-id-type="pmid">
       35418180
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9007937
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41408-022-00660-2
      </pub-id>
      <elocation-id>
       61
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR20">
     <label>
      20.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Albinger
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia
      </article-title>
      <source>
       Bone Marrow Transpl.
      </source>
      <year>
       2024
      </year>
      <volume>
       59
      </volume>
      <fpage>
       489
      </fpage>
      <lpage>
       495
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXhvFartb0%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41409-023-02180-4
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR21">
     <label>
      21.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Braud
        </surname>
        <given-names>
         VM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
      </article-title>
      <source>
       Nature
      </source>
      <year>
       1998
      </year>
      <volume>
       391
      </volume>
      <fpage>
       795
      </fpage>
      <lpage>
       799
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       1998Natur.391..795B
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DyaK1cXhtlCjtbo%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       9486650
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/35869
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR22">
     <label>
      22.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Le Dréan
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases
      </article-title>
      <source>
       Eur. J. Immunol.
      </source>
      <year>
       1998
      </year>
      <volume>
       28
      </volume>
      <fpage>
       264
      </fpage>
      <lpage>
       276
      </lpage>
      <pub-id pub-id-type="pmid">
       9485206
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1002/(SICI)1521-4141(199801)28:01&lt;264::AID-IMMU264&gt;3.0.CO;2-O
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR23">
     <label>
      23.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         André
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells
      </article-title>
      <source>
       Cell
      </source>
      <year>
       2018
      </year>
      <volume>
       175
      </volume>
      <fpage>
       1731
      </fpage>
      <lpage>
       1743.e13
      </lpage>
      <pub-id pub-id-type="pmid">
       30503213
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6292840
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cell.2018.10.014
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR24">
     <label>
      24.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Tognarelli
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Enhancing the activation and releasing the brakes: a double hit strategy to improve NK cell cytotoxicity against multiple myeloma
      </article-title>
      <source>
       Front Immunol.
      </source>
      <year>
       2018
      </year>
      <volume>
       9
      </volume>
      <fpage>
       2743
      </fpage>
      <pub-id pub-id-type="pmid">
       30542346
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6277768
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2018.02743
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR25">
     <label>
      25.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bexte
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma
      </article-title>
      <source>
       Oncoimmunology
      </source>
      <year>
       2022
      </year>
      <volume>
       11
      </volume>
      <pub-id pub-id-type="pmid">
       35694192
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9176243
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1080/2162402X.2022.2081415
      </pub-id>
      <elocation-id>
       2081415
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR26">
     <label>
      26.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bexte
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <name>
        <surname>
         Reindl
        </surname>
        <given-names>
         LM
        </given-names>
       </name>
       <name>
        <surname>
         Ullrich
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Nonviral technologies can pave the way for CAR-NK cell therapy
      </article-title>
      <source>
       J. Leukoc. Biol.
      </source>
      <year>
       2023
      </year>
      <volume>
       114
      </volume>
      <fpage>
       475
      </fpage>
      <lpage>
       486
      </lpage>
      <pub-id pub-id-type="pmid">
       37403203
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/jleuko/qiad074
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR27">
     <label>
      27.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Holling
        </surname>
        <given-names>
         TM
        </given-names>
       </name>
       <name>
        <surname>
         Schooten
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <name>
        <surname>
         van Den Elsen
        </surname>
        <given-names>
         PJ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men
      </article-title>
      <source>
       Hum. Immunol.
      </source>
      <year>
       2004
      </year>
      <volume>
       65
      </volume>
      <fpage>
       282
      </fpage>
      <lpage>
       290
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2cXjs1Gitrc%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       15120183
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.humimm.2004.01.005
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR28">
     <label>
      28.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Post
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The transcription factor ZNF683/HOBIT regulates human NK-cell development
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2017
      </year>
      <volume>
       8
      </volume>
      <fpage>
       535
      </fpage>
      <pub-id pub-id-type="pmid">
       28555134
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5430038
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2017.00535
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR29">
     <label>
      29.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Metkar
        </surname>
        <given-names>
         SS
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis
      </article-title>
      <source>
       J. Cell Biol.
      </source>
      <year>
       2003
      </year>
      <volume>
       160
      </volume>
      <fpage>
       875
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD3sXitlSltrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       12629051
      </pub-id>
      <pub-id pub-id-type="pmcid">
       2173758
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1083/jcb.200210158
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR30">
     <label>
      30.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Jayavelu
        </surname>
        <given-names>
         AK
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The proteogenomic subtypes of acute myeloid leukemia
      </article-title>
      <source>
       Cancer Cell
      </source>
      <year>
       2022
      </year>
      <volume>
       40
      </volume>
      <fpage>
       301
      </fpage>
      <lpage>
       317.e12
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XlvVekurs%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       35245447
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ccell.2022.02.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR31">
     <label>
      31.
     </label>
     <mixed-citation publication-type="other">
      013062 - NSG-SGM3 Strain Details.
      <ext-link ext-link-type="uri" xlink:href="https://www.jax.org/strain/013062">
       https://www.jax.org/strain/013062#
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR32">
     <label>
      32.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wunderlich
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
      </article-title>
      <source>
       Leukemia
      </source>
      <year>
       2010
      </year>
      <volume>
       24
      </volume>
      <fpage>
       1785
      </fpage>
      <lpage>
       1788
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC3cfovVWmug%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       20686503
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5439963
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/leu.2010.158
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR33">
     <label>
      33.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rasheed
        </surname>
        <given-names>
         HM
        </given-names>
       </name>
       <name>
        <surname>
         Donia
        </surname>
        <given-names>
         HM
        </given-names>
       </name>
       <name>
        <surname>
         Nadwan
        </surname>
        <given-names>
         EA
        </given-names>
       </name>
       <name>
        <surname>
         Mourad
        </surname>
        <given-names>
         ZI
        </given-names>
       </name>
       <name>
        <surname>
         Farahat
        </surname>
        <given-names>
         N
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Identifying leukemia-associated immunophenotypes in acute myeloid leukemia patients using multiparameter flow cytometry
      </article-title>
      <source>
       Oman Med. J.
      </source>
      <year>
       2021
      </year>
      <volume>
       36
      </volume>
      <fpage>
       e323
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xht1SltL%2FP
      </pub-id>
      <pub-id pub-id-type="pmid">
       35024173
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8722324
      </pub-id>
      <pub-id pub-id-type="doi">
       10.5001/omj.2021.108
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR34">
     <label>
      34.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Heuser
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2021
      </year>
      <volume>
       138
      </volume>
      <fpage>
       2753
      </fpage>
      <lpage>
       2767
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XislGqsg%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       34724563
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8718623
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2021013626
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR35">
     <label>
      35.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ruggeri
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
      </article-title>
      <source>
       Science
      </source>
      <year>
       2002
      </year>
      <volume>
       295
      </volume>
      <fpage>
       2097
      </fpage>
      <lpage>
       2100
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2002Sci...295.2097R
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD38Xit1Ohurs%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       11896281
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1126/science.1068440
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR36">
     <label>
      36.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wendel
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Arming immune cells for battle: a brief journey through the advancements of T and NK cell immunotherapy
      </article-title>
      <source>
       Cancers (Basel)
      </source>
      <year>
       2021
      </year>
      <volume>
       13
      </volume>
      <fpage>
       1481
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhslClsL3K
      </pub-id>
      <pub-id pub-id-type="pmid">
       33807011
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3390/cancers13061481
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR37">
     <label>
      37.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Cooley
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
      </article-title>
      <source>
       Blood Adv.
      </source>
      <year>
       2019
      </year>
      <volume>
       3
      </volume>
      <fpage>
       1970
      </fpage>
      <lpage>
       1980
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVKgsLjM
      </pub-id>
      <pub-id pub-id-type="pmid">
       31266741
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6616260
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/bloodadvances.2018028332
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR38">
     <label>
      38.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Crinier
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia
      </article-title>
      <source>
       Cell Mol. Immunol.
      </source>
      <year>
       2021
      </year>
      <volume>
       18
      </volume>
      <fpage>
       1290
      </fpage>
      <lpage>
       1304
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXisVWnt7jM
      </pub-id>
      <pub-id pub-id-type="pmid">
       33239726
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41423-020-00574-8
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR39">
     <label>
      39.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Dufva
        </surname>
        <given-names>
         O
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers
      </article-title>
      <source>
       Immunity
      </source>
      <year>
       2023
      </year>
      <volume>
       56
      </volume>
      <fpage>
       2816
      </fpage>
      <lpage>
       2835.e13
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXis1WntLfF
      </pub-id>
      <pub-id pub-id-type="pmid">
       38091953
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.immuni.2023.11.008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR40">
     <label>
      40.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Schneider
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A unique human immunoglobulin heavy chain variable domain-only CD33 CAR for the treatment of acute myeloid leukemia
      </article-title>
      <source>
       Front. Oncol.
      </source>
      <year>
       2018
      </year>
      <volume>
       8
      </volume>
      <fpage>
       539
      </fpage>
      <pub-id pub-id-type="pmid">
       30524966
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6262782
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fonc.2018.00539
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR41">
     <label>
      41.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hejazi
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       CD33 delineates two functionally distinct NK cell populations divergent in cytokine production and antibody-mediated cellular cytotoxicity
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2021
      </year>
      <volume>
       12
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtFels7nE
      </pub-id>
      <pub-id pub-id-type="pmid">
       35058934
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2021.798087
      </pub-id>
      <elocation-id>
       798087
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR42">
     <label>
      42.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hunt
        </surname>
        <given-names>
         JMT
        </given-names>
       </name>
       <name>
        <surname>
         Samson
        </surname>
        <given-names>
         CA
        </given-names>
       </name>
       <name>
        <surname>
         Rand
        </surname>
        <given-names>
         Adu
        </given-names>
       </name>
       <name>
        <surname>
         Sheppard
        </surname>
        <given-names>
         HM
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells
      </article-title>
      <source>
       Hum. Genet.
      </source>
      <year>
       2023
      </year>
      <volume>
       142
      </volume>
      <fpage>
       705
      </fpage>
      <lpage>
       720
      </lpage>
      <pub-id pub-id-type="pmid">
       37093294
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10182114
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s00439-023-02561-1
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR43">
     <label>
      43.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rad
        </surname>
        <given-names>
         SMAH
        </given-names>
       </name>
       <name>
        <surname>
         Poudel
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Tan
        </surname>
        <given-names>
         GMY
        </given-names>
       </name>
       <name>
        <surname>
         McLellan
        </surname>
        <given-names>
         AD
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Promoter choice: Who should drive the CAR in T cells?
      </article-title>
      <source>
       PLoS ONE
      </source>
      <year>
       2020
      </year>
      <volume>
       15
      </volume>
      <fpage>
       e0232915
      </fpage>
      <pub-id pub-id-type="doi">
       10.1371/journal.pone.0232915
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR44">
     <label>
      44.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Klermund
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       On- and off-target effects of paired CRISPR-Cas nickase in primary human cells
      </article-title>
      <source>
       Mol. Ther.
      </source>
      <year>
       2024
      </year>
      <volume>
       32
      </volume>
      <fpage>
       1298
      </fpage>
      <lpage>
       1310
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXmtFGms7o%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       38459694
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ymthe.2024.03.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR45">
     <label>
      45.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Turchiano
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq
      </article-title>
      <source>
       Cell Stem Cell
      </source>
      <year>
       2021
      </year>
      <volume>
       28
      </volume>
      <fpage>
       1136
      </fpage>
      <lpage>
       1147.e5
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXltFOmurY%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33626327
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.stem.2021.02.002
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR46">
     <label>
      46.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nguyen
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT
      </article-title>
      <source>
       Bone Marrow Transpl.
      </source>
      <year>
       2009
      </year>
      <volume>
       43
      </volume>
      <fpage>
       693
      </fpage>
      <lpage>
       699
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXlvVGrsL0%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/bmt.2008.380
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR47">
     <label>
      47.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Biederstädt
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Rezvani
        </surname>
        <given-names>
         K
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2023
      </year>
      <volume>
       141
      </volume>
      <fpage>
       22
      </fpage>
      <lpage>
       38
      </lpage>
      <pub-id pub-id-type="pmid">
       35512203
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2021012411
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR48">
     <label>
      48.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Majzner
        </surname>
        <given-names>
         RG
        </given-names>
       </name>
       <name>
        <surname>
         Mackall
        </surname>
        <given-names>
         CL
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Clinical lessons learned from the first leg of the CAR T cell journey
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2019
      </year>
      <volume>
       25
      </volume>
      <fpage>
       1341
      </fpage>
      <lpage>
       1355
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXhslelurbN
      </pub-id>
      <pub-id pub-id-type="pmid">
       31501612
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41591-019-0564-6
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR49">
     <label>
      49.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Daher
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2021
      </year>
      <volume>
       137
      </volume>
      <fpage>
       624
      </fpage>
      <lpage>
       636
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXjvVemsb8%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       32902645
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7869185
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2020007748
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR50">
     <label>
      50.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Jo
        </surname>
        <given-names>
         D-H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles
      </article-title>
      <source>
       Mol. Ther. Methods Clin. Dev.
      </source>
      <year>
       2023
      </year>
      <volume>
       29
      </volume>
      <fpage>
       173
      </fpage>
      <lpage>
       184
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXmsFOgs7w%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       37063482
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10102412
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.omtm.2023.03.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR51">
     <label>
      51.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lupo
        </surname>
        <given-names>
         KB
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2024
      </year>
      <volume>
       15
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2024NatCo..15.1909L
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXlsVKmsrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       38429294
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10907695
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-024-46343-3
      </pub-id>
      <elocation-id>
       1909
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR52">
     <label>
      52.
     </label>
     <mixed-citation publication-type="other">
      Research, C. for B. E. and. FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies.
      <italic>
       FDA
      </italic>
      (2023).
     </mixed-citation>
    </ref>
    <ref id="CR53">
     <label>
      53.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bexte
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors
      </article-title>
      <source>
       Mol. Ther.
      </source>
      <year>
       2024
      </year>
      <volume>
       32
      </volume>
      <fpage>
       2357
      </fpage>
      <lpage>
       2372
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXht1ajtbvJ
      </pub-id>
      <pub-id pub-id-type="pmid">
       38751112
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ymthe.2024.05.022
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR54">
     <label>
      54.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kath
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2024
      </year>
      <volume>
       143
      </volume>
      <fpage>
       2599
      </fpage>
      <lpage>
       2611
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXhtlOgtbnL
      </pub-id>
      <pub-id pub-id-type="pmid">
       38493479
      </pub-id>
      <pub-id pub-id-type="pmcid">
       11196866
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2023020973
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR55">
     <label>
      55.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Müller
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia
      </article-title>
      <source>
       Front Immunol.
      </source>
      <year>
       2019
      </year>
      <volume>
       10
      </volume>
      <fpage>
       3123
      </fpage>
      <pub-id pub-id-type="pmid">
       32117200
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2019.03123
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR56">
     <label>
      56.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Colamartino
        </surname>
        <given-names>
         ABL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2019
      </year>
      <volume>
       10
      </volume>
      <fpage>
       2873
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVCgtrbO
      </pub-id>
      <pub-id pub-id-type="pmid">
       31921138
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6927467
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2019.02873
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR57">
     <label>
      57.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bari
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A distinct subset of highly proliferative and lentiviral vector (LV)-transducible NK cells define a readily engineered subset for adoptive cellular therapy
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2019
      </year>
      <volume>
       10
      </volume>
      <fpage>
       2001
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXks1Squ70%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       31507603
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6713925
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2019.02001
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR58">
     <label>
      58.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Alzubi
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Automated generation of gene-edited CAR T cells at clinical scale
      </article-title>
      <source>
       Mol. Ther. Methods Clin. Dev.
      </source>
      <year>
       2021
      </year>
      <volume>
       20
      </volume>
      <fpage>
       379
      </fpage>
      <lpage>
       388
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2021tktf.book.....A
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXjtVSqt7o%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33575430
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.omtm.2020.12.008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR59">
     <label>
      59.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Livak
        </surname>
        <given-names>
         KJ
        </given-names>
       </name>
       <name>
        <surname>
         Schmittgen
        </surname>
        <given-names>
         TD
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
      </article-title>
      <source>
       Methods
      </source>
      <year>
       2001
      </year>
      <volume>
       25
      </volume>
      <fpage>
       402
      </fpage>
      <lpage>
       408
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD38XhtFelt7s%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       11846609
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1006/meth.2001.1262
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR60">
     <label>
      60.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Riedel
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       An extended ΔCT-method facilitating normalisation with multiple reference genes suited for quantitative RT-PCR analyses of human hepatocyte-like cells
      </article-title>
      <source>
       PLoS ONE
      </source>
      <year>
       2014
      </year>
      <volume>
       9
      </volume>
      <fpage>
       e93031
      </fpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2014PLoSO...993031R
      </pub-id>
      <pub-id pub-id-type="pmid">
       24658132
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3962476
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1371/journal.pone.0093031
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR61">
     <label>
      61.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Campbell
        </surname>
        <given-names>
         KR
        </given-names>
       </name>
       <name>
        <surname>
         Lun
        </surname>
        <given-names>
         ATL
        </given-names>
       </name>
       <name>
        <surname>
         Wills
        </surname>
        <given-names>
         QF
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R
      </article-title>
      <source>
       Bioinformatics
      </source>
      <year>
       2017
      </year>
      <volume>
       33
      </volume>
      <fpage>
       1179
      </fpage>
      <lpage>
       1186
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXhvFagtL%2FP
      </pub-id>
      <pub-id pub-id-type="pmid">
       28088763
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5408845
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/bioinformatics/btw777
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR62">
     <label>
      62.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ilicic
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Classification of low quality cells from single-cell RNA-seq data
      </article-title>
      <source>
       Genome Biol.
      </source>
      <year>
       2016
      </year>
      <volume>
       17
      </volume>
      <pub-id pub-id-type="pmid">
       26887813
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4758103
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s13059-016-0888-1
      </pub-id>
      <elocation-id>
       29
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR63">
     <label>
      63.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         AITCHISON
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         HO
        </surname>
        <given-names>
         CH
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The multivariate Poisson-log normal distribution
      </article-title>
      <source>
       Biometrika
      </source>
      <year>
       1989
      </year>
      <volume>
       76
      </volume>
      <fpage>
       643
      </fpage>
      <lpage>
       653
      </lpage>
      <pub-id assigning-authority="American Mathematical Society" pub-id-type="other">
       1041409
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/biomet/76.4.643
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR64">
     <label>
      64.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Robinson
        </surname>
        <given-names>
         MD
        </given-names>
       </name>
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Smyth
        </surname>
        <given-names>
         GK
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
      </article-title>
      <source>
       Bioinformatics
      </source>
      <year>
       2010
      </year>
      <volume>
       26
      </volume>
      <fpage>
       139
      </fpage>
      <lpage>
       140
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXhs1WlurvO
      </pub-id>
      <pub-id pub-id-type="pmid">
       19910308
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/bioinformatics/btp616
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR65">
     <label>
      65.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ritchie
        </surname>
        <given-names>
         ME
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       limma powers differential expression analyses for RNA-sequencing and microarray studies
      </article-title>
      <source>
       Nucleic Acids Res.
      </source>
      <year>
       2015
      </year>
      <volume>
       43
      </volume>
      <fpage>
       e47
      </fpage>
      <pub-id pub-id-type="pmid">
       25605792
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4402510
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/nar/gkv007
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR66">
     <label>
      66.
     </label>
     <mixed-citation publication-type="other">
      Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments.
      <italic>
       Stat. Appl. Genet. Mol. Biol.
      </italic>
      <bold>
       3
      </bold>
      , 3 (2004).
     </mixed-citation>
    </ref>
    <ref id="CR67">
     <label>
      67.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Phipson
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         Lee
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Majewski
        </surname>
        <given-names>
         IJ
        </given-names>
       </name>
       <name>
        <surname>
         Alexander
        </surname>
        <given-names>
         WS
        </given-names>
       </name>
       <name>
        <surname>
         Smyth
        </surname>
        <given-names>
         GK
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression
      </article-title>
      <source>
       Ann. Appl Stat.
      </source>
      <year>
       2016
      </year>
      <volume>
       10
      </volume>
      <fpage>
       946
      </fpage>
      <lpage>
       963
      </lpage>
      <pub-id assigning-authority="American Mathematical Society" pub-id-type="other">
       3528367
      </pub-id>
      <pub-id pub-id-type="pmid">
       28367255
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5373812
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1214/16-AOAS920
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR68">
     <label>
      68.
     </label>
     <mixed-citation publication-type="other">
      Wickham, H.
      <italic>
       Ggplot2
      </italic>
      (Springer International Publishing, 2016).
      <ext-link ext-link-type="doi" xlink:href="10.1007/978-3-319-24277-4">
       https://doi.org/10.1007/978-3-319-24277-4
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR69">
     <label>
      69.
     </label>
     <mixed-citation publication-type="other">
      The igraph software package for complex network research|BibSonomy.
      <ext-link ext-link-type="uri" xlink:href="https://www.bibsonomy.org/bibtex/bb49a4a77b42229a427fec316e9fe515">
       https://www.bibsonomy.org/bibtex/bb49a4a77b42229a427fec316e9fe515
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR70">
     <label>
      70.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Blondel
        </surname>
        <given-names>
         VD
        </given-names>
       </name>
       <name>
        <surname>
         Guillaume
        </surname>
        <given-names>
         J-L
        </given-names>
       </name>
       <name>
        <surname>
         Lambiotte
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <name>
        <surname>
         Lefebvre
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Fast unfolding of communities in large networks
      </article-title>
      <source>
       J. Stat. Mech.
      </source>
      <year>
       2008
      </year>
      <volume>
       2008
      </volume>
      <fpage>
       P10008
      </fpage>
      <pub-id pub-id-type="doi">
       10.1088/1742-5468/2008/10/P10008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR71">
     <label>
      71.
     </label>
     <mixed-citation publication-type="other">
      Raivo Kolde. pheatmap: Pretty Heatmaps. 1.0.12
      <ext-link ext-link-type="doi" xlink:href="10.32614/CRAN.package.pheatmap">
       https://doi.org/10.32614/CRAN.package.pheatmap
      </ext-link>
      (2010).
     </mixed-citation>
    </ref>
    <ref id="CR72">
     <label>
      72.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lun
        </surname>
        <given-names>
         ATL
        </given-names>
       </name>
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Marioni
        </surname>
        <given-names>
         JC
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor
      </article-title>
      <source>
       F1000Res
      </source>
      <year>
       2016
      </year>
      <volume>
       5
      </volume>
      <fpage>
       2122
      </fpage>
      <pub-id pub-id-type="pmid">
       27909575
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5112579
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR73">
     <label>
      73.
     </label>
     <mixed-citation publication-type="other">
      van der Maaten, L. &amp; Hinton, G. Visualizing Data using t-SNE.
      <italic>
       J. Mach. Learn. Res.
      </italic>
      <bold>
       9
      </bold>
      , 2579–2605 (2008).
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec41">
     <title>
      Taarifa za Ziada
     </title>
     <p id="Par61">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM2_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Peer Review File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM3_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Description of Additional Supplementary Files
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM4" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM4_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 1
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM5" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM5_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 2
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM6" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM6_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 3
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM7" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM7_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 4
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM8" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM8_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 5
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM9" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM9_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Reporting Summary
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
    <sec id="Sec42">
     <title>
      Data ya Chanzo
     </title>
     <p id="Par62">
      <supplementary-material content-type="local-data" id="MOESM10" xlink:title="Source data">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM10_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Source data
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title>
    Taarifa za Ziada
   </title>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41467-024-52388-1">
     https://doi.org/10.1038/s41467-024-52388-1
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <p>
    <bold>
     Publisher’s note
    </bold>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
